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Mesoporous Silicon Micro- and 
Nanoparticles – A Versatile Tool for 
Peptide Delivery
It is likely that peptides will increase 
their share of pharmaceuticals 
replacing the traditional drug 
compounds, but their successful 
delivery is challenged by 
their physicochemical and 
pharmacokinetic properties. 
Therefore, improved delivery 
systems are needed to facilitate the 
clinical use of peptides. In this thesis, 
mesoporous silicon was demonstrated 
to be suitable and tuneable material 

















































































































































It is likely that peptides will increase their share of pharmaceuticals replacing the
traditional drug compounds due to their advantages, such as target specifity and
tolerability. However, successful delivery of peptides is challenging due to the unique
propertiesofthesecompounds,suchastheirshorthalflivesandpoororalbioavailabilities.
Therefore, improved peptide delivery systems are needed, for example, to prolong their
effectsandlowertheadministrationfrequency.
Here, mesoporous silicon (PSi) was investigated for use in peptide delivery. The
advantagesofPSiincludethefaciledrugloadingprocedure,abilitytocarryhighpayloads,
biocompatibility and biodegradability. PSi has not been investigated extensively for
peptide delivery or in vivo, although it has attracted substantial interest in various
biomedical applications.Threeappetite regulatingpeptides,ghrelinantagonist (GhA,Mw
930 g/mol),melanotan II (MTII,Mw 1024 g/mol) and peptide YY336 (PYY336,Mw 4050
g/mol)wereusedasmodelpeptides.
First, the capability of PSi to deliver biologically active peptides was investigated by
loadingGhAandMTIIintothermallyhydrocarbonizedPSi(THCPSi)microparticlesandby
comparing the effects to the corresponding solutions after subcutaneous (s.c.)delivery in
miceandrats.THCPSimicroparticleswereshowntoprolonganddelaytheeffectsofGhA
andMTII,whichwasconsideredasanevidenceofsustainedreleaseofactivepeptides.






PYY336 over several days. The surface chemistry of PSi microparticles significantly
affectedthePYY336releaseasonlythemosthydrophilicsurface,thermallyoxidizedPSi,




To investigate the effect of administration routes on PYY336 delivery via PSi
nanocarriers, s.c. and i.v. administrationwere evaluated. Interestingly, in contrast to s.c.
administration, after i.v. delivery the PSi nanocarrier surface chemistry did affect the
release of PYY336. Themost hydrophobic form, thermally hydrocarbonized PSi, had an
absolutebioavailabilityofabout50%,whereastheothersurfacesachievedbioavailabilities
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turvallisuuden vuoksi. Peptidien erityispiirteiden, esimerkiksi nopean eliminaation takia
niiden annostelu on haastavaa. Tästä syystä peptidilääkkeille tarvitaan parempia
saattomenetelmiätehostamaanannosteluajapidentämäänvaikutuksia.
Tässä työssä tutkittiin mesohuokoista piitä (PSi) peptidiannostelussa. Vaikka PSi on
herättänyt mielenkiintoa useissa lääketieteen sovelluksissa, sitä ei ole laajalti tutkittu
peptidiannostelussa eikä in vivo. PSi:n etuja ovat esimerkiksi hellävarainen lääkeaineen
latausmenetelmä, korkea latausaste, biologinen yhteensopivuus ja hajoavuus annostelun
jälkeen. Tässä työssä käytettiin malliaineina ruokahalun säätelyyn liittyviä peptidejä;




vaikutuksia vastaaviin liuoksiin ihonalaisen (s.c.) annostelun jälkeen hiirillä ja rotilla.
THCPSimikropartikkelitpidensivätpeptidienvaikutuksiaosoittaenbiologisestiaktiivisten
peptidienvapautuvanviivästyneesti.
Koska parenteraaliset kantajamateriaalit voivat aiheuttaa tulehduksellisia reaktioita,
plasman sytokiinipitoisuudet mitattiin hiiriltä PSimikro (s.c.) ja nanopartikkelien (i.v.)
kertaannoksen jälkeen. Tulokset tukivat aikaisempia tutkimuksia PSi:n turvallisuudesta,
silläsytokiinipitoisuuksissaeihavaittumuutoksiaverrattunakontrolliliuokseen.
PSi:n pintakemian vaikutusta PYY336:n s.c. annosteluun selvitettiin hiirillä. Kaikki
tutkitut PSi formulaatiot paransivat PYY336:n s.c. farmakokinetiikkaa ja kontrolloivat
vapautumistauseanpäivän ajan. PSimikropartikkelienpintakemiavaikuttimerkittävästi
PYY336:n vapautumiseen, koska vain hydrofiilisin, termaalisesti oksidoitu PSi vapautti
peptidin täydellisesti. Sitä vastoin kaikki s.c. PSinanoformulaatiot vapauttivat PYY336:n
täydellisesti eikä pintakemia vaikuttanut peptidin vapautumiseen merkittävästi. Lisäksi
PSinanopartikkelit saivat aikaan tasaisemman PYY336:n plasmapitoisuuden verrattuna
PSimikropartikkeleihin.
Kun s.c. ja i.v. antoreittejä vertailtiin PYY336:n annostelussa PSinanopartikkeleissa,
viivästynyt vapautuminen havaittiin vain s.c. annostelun jälkeen. Päinvastoin kuin s.c.
annostelussa, i.v. annostelussa PSinanopartikkelien pintakemia vaikutti PYY336:n
vapautumiseen.PYY336:nabsoluuttinenbiologinenhyväksikäytettävyysolinoin50%i.v.
annostelun jälkeen hydrofobisimmissa termaalisesti hydrokarbidoiduissa PSi
nanopartikkeleissa, kun taas muilla pintakemioilla PYY336:n biologinen
hyväksikäytettävyysolilähes100%.
PSimahdollistaaruokahaluasäätelevienpeptidiens.c.annostelunviivästyneestiuseiden
päivien ajan säilyttäen peptidien aktiivisuuden. Erityisesti nanopartikkelit tehostivat s.c.
peptidiannostelua. Tulokset rohkaisevat jatkamaan PSi:n kehittämistä ja tutkimista
monipuolisenamateriaalinapeptidiannostelussa.
Luokitus:QT36.5,QT37,QU68,QV38,QV785,QV525,WK170,WK185
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Many peptides and proteins are now on the market as therapeutical substances and
furthermore,novelmembersofthesegroupsarebeingintenselyinvestigatedinthetreatment
ofmanyseriouspathological conditions, suchascancer, type2diabetes,multiple sclerosis,
but also for disease prevention, e.g. vaccines (Walsh 2010).Over 25% of theUS Food and
Drug Administration’s (FDA) drug approvals were biologic drugs in 2010 and they are
expectedtofurtherincreasetheirshareofthemarket(Mullard2011).During2009–2011,eight
peptideswere approved by FDA; these included therapies for type2 diabetes (liraglutide,
Victoza),hepatitisC(boceprevir,Victrelis),lymphomas(brentuximabvedotin,Adcetris)and
skin infections (telavancin,Vibativ) (Albericio andKruger 2012). Theultimate challenge in
using peptides as pharmaceutical compounds is related to their high molecular weight,
varying solubility, low ability to penetrate through biological membranes and their
susceptibility to rapiddegradation in the body leading to a short halflife (Antosova et al.
2009). Consequently, their administration often takes place by repeated injections that, in
additiontothediscomfortinvolved,mightresultinfluctuatingdrugplasmaconcentrations
causingeithersideeffectsortheriskthattheywillbeineffective.Therefore,thedevelopment
of controlled peptide delivery systems could improve both, drug safety and patient
compliance.
 Peptidesconsistofaminoacids,insulinbeingherethelargestwith51aminoacids(Latham
1999). Peptides participate in various physiological processes as hormones, for example,
insulin regulates glucose homeostasis. These agents also play a major role in regulating
energyhomeostasisandappetitecontrol(Stanleyetal.2005).Theregulativesystemoffood
intake iscomplex, thehypothalamusbeingthe integratingcentreforperipheralandcentral
signalsofnutritionalstatus,furtheraccompaniedbyhedonicfactors(Berthoud2011;Samet
al. 2012).As obesity is a global health problem and efficientweightloss therapies are still
lacking,thisthemeisunderintensiveinvestigationbothinachievingabetterunderstandof
the mechanisms controlling appetite regulation and obesity and in discovering molecular
targetsforantiobesitytherapies(PadwalandMajumdar2007).Inrecentyears,severalanti
obesity drugs have been available, but theirmarketing has often been hampered by poor
efficacy and diverse safety related issues (Rodgers et al. 2012). Today, several new anti
obesitytargetsareunderinvestigation,includinggutderivedhormonesinvolvedinappetite
regulation (Kennett and Clifton 2010; Powell et al. 2011). However, while their peptide
structuremaymake them interesting drug targets, the challenges related to their delivery
needtobeovercome.
 Onewaytoimprovedrugandpeptidedeliveryistoutilizeparticulatecarriersystems,for
example, to prevent the compound from premature degradation (Tang et al. 2004). For
example,mesoporoussilicahasbeeninvestigatedasaparticulatecarriersystemindifferent
applicationsandithasbeenclaimedtoimprovethetherapeuticefficacyofanticancerdrugs




and inorganicmaterials, such as liposomes,polymericparticles anddendrimershavebeen
developed and investigated (Bawarski et al. 2008). In the case of peptides, their delicate
characteristics pose challenges to the formulation process, which may affect the peptide’s
bioactivity (Jiskoot et al. 2012).Nanotechnology represents interestingways tomodify the





marketed (Zhang et al. 2008; Malam et al. 2011). In addition to achieving a better
pharmacokineticprofile,forexamplebyproducingcontrolleddrugrelease,nanoparticlescan
be targeted to specific tissues,whichallows thedrugdose tobe reduced, systemic toxicity
minimized and several administration routesmay be applied (Malam et al. 2011).Various
particulate systems have been investigated also for peptides including liposomes, dextran
nanoparticles and polyethylene glycol microparticles (Chalasani et al. 2007; Werle and
Takeuchi 2009; Tewes et al. 2011). During recent years, porous silicon (PSi) has been
investigatedforitsapplicationsindrugdeliveryduetoitsadvantageousproperties,suchas
biocompatibility, easily tuneable surface properties, good drug loading capacity and
improved dissolution of poorly soluble drugs (Anglin et al. 2008; Salonen et al. 2008;
Jaganathan and Godin 2012). Compared with existing peptide delivery materials, such as




 The aim of the present studywas to investigate the suitability of using PSi for peptide
delivery, in particular to achieve a controlled peptide release system using appetite

















blood pressure, central nervous system and cancer (Malavolta and Cabral 2011). In this
review,peptidesareconsideredtoconsistofchainsofnomorethan50aminoacids,withthe
exception of insulin (51 amino acids). Insulin was the first pharmaceutical peptide to be
utilized for the treatment of diabetes in 1922, changing the life of diabetes patients
dramatically (Banting et al. 1922). In particular, in recent decades, the advances of
biotechnology and recombinant DNA techniques have enabled commercial production of
therapeuticproteinsandpeptides.Severalpeptidesandproteinshaveenteredthemarketas
medical drugs offering cures or relief of symptoms for several previously untreatable
illnesses,suchasHER2positivebreastcancer(Table2.1)(PloskerandKeam2006).
 Peptides are a group of compounds which have stimulated interest as potential
therapeutical compounds. Currently, over 200 biopharmaceutical products are marketed,
including about 80 peptides, and their proportion of the small molecular weight drug
molecules isgrowing(Table2.1)(Walsh2010;AlbericioandKruger2012).Peptidespossess
severaladvantageouspropertiescomparedwithsmallmoleculedrugs.Forexample,theyare
highly specific and thus less likely to interfere with biological functions and due to their
naturalorigins theyareoftenwelltoleratedwithout toxicmetabolitesas theydegrade into
amino acids (Leader et al. 2008). However, special features of peptides make them
challengingaspharmaceuticalmolecules.Dependingonthesizeofthepeptide,thehalflife
canbe as short as a fewminutes or rarelymore than a fewhours. In fact, the smaller the
peptidethefasteritwillbedegraded(Latham1999).Whenconsideringoralpeptidedelivery,
the medication cost might well become prohibitive due to the extremely poor oral
bioavailability. Fortunately, the doses of peptide therapeutics are usually very low.
Interestingly,peptidesmight even reach themarketmorequickly sinceentrance to clinical
phases could be quite rapid i.e. the drug discovery phase may be shortened, due to the






severe combined immunodeficiency disease (Adagen) and lasparaginase (Oncaspar) for
leukemia (SigmaTauPharmaceuticals Inc.2012).However,despite theobviousadvantages
ofusingPEG,suchasresistancetoproteolysis,increasedhalflife,lowerrenalclearanceand
decreased immunogenicity, this technique may also compromise the peptide’s biological
activity in somecases (Brown2005).PEGylationchanges thephysicochemicalpropertiesof
thepeptide,whichmayinfluenceitsbindingaffinitytothetargetreceptorsandsubsequently
changethebioactivity.ThishasbeenshowntobedependentonthePEGbeingused(Harris














particular,moleculeswhicharederived fromadifferentspecieshavea tendency to induce
antibody formation. For example, the first insulin products, derived from cows and pigs,
weremoreallergenicthanthecurrentproducts,whichhaveasimilaraminoacidsequenceto
human insulin (Ghazavi and Johnston 2011). Today, there is an increasing risk that
previouslyusedbiotherapeuticsmightpredispose towards immune responses causedby a




of renal anemia, which can induce formation of erythropoietin neutralizing antibodies
(RossertandPureRedCellAplasiaGlobalScientificAdvisoryBoard(GSAB)2005).Theside
effectsofpeptidesareusuallytargetmediatedorduetoexaggeratedpharmacology.
 Even thoughmuch effort has been expended on trying tomake peptide deliverymore
efficiente.g.bydevelopingcontrolledreleaseornoninvasivedeliverysystems,peptidesare

















































































































































































































































































































































































































































































































































































































































































































































an efficient per oral delivery remains still as a challenge. In general terms, after
administration,peptidesneedtobeabsorbedfromthedeliverysite intothecirculationand
then to be distributed to reach their targets before they can evoke the desired responses.






Os) and these same rules can be applied to peptides (Lipinski et al. 2001). Therefore, in
generalpassive transportationofpeptidesviaparaand transcellular routes isvery limited




 Distribution of peptides is usually limited and affected by their physical and chemical
properties, routeofadministration,but it canalsobe targetmediatedwhen the interaction
with the target activates both the pharmacological function and drug elimination
(Vugmeyster et al. 2012).Generally, themicrovascularwalls have pores in a size range of
either <10 nm or 25–70 nm allowing the peptides to extravasate from the circulation to
interstitialfluidandfurthertotheirtargetreceptorsonthecellsurface(Lin2009).Incertain
tissues,thecapillaryendotheliumismorepermeableasitisdiscontinuous(liver,spleen)or
fenestrated (renal glomeluri, intestinal villi) allowing transportation of a larger molecules
(1000–10000and50–800nm,respectively)(Vugmeysteretal.2012).
 The major route of elimination for peptide drugs is rapid metabolism by peptidases;
similarly to endogenous and ingested peptides or proteins, therefore, in general, it is not
necessarytoevaluatetoxicmetabolitesoftherapeuticpeptides.Asthetranscellulardiffusion
of peptides is limited, the proteolytic enzymes in the cytosol do not generally play an
importantroleinpeptidedegradation(BernkopSchnurch1998).Small(<10kDa)andwater
solublepeptidescanbefreelyexcretedviathekidneys(Lin2009).
 In conclusion, several factors hinder peptide absorption after oral delivery,making this
mostconvenientdeliveryroutealsothemostchallenging.Withrespecttotheoftherapeutical






al. 2012). The absorption rate and extent of peptides or proteins from the s.c. space is
generally slowand theblood capillarieswith their continuous layer of epithelia creates an
effectiveabsorptionbarrier forpeptides (PorterandCharman2000).Although the invasive
s.c.injectionbypassesfirstpassmetabolismanddeliversthetotaldoseintothes.c.space,the
absolutebioavailabilitymightremainunder100%(Table2.1)andtodate,thepathwaysand
mechanisms of s.c. peptide absorption into systemic circulation are not completely clear
(Vugmeyster et al. 2012). For example, the absorptions of peptide YY336 (PYY336) and
PEGylatederythropoietinhavebeenreportedtobe limitedafters.c.administrationas their







Mw 7.65 kDa, Increlex) has an absolute bioavailability of 100% (Vugmeyster et al. 2012).
Dependingon the sizeof thepeptidedrug, theabsorptionmayoccureitherviaperipheral




the circulation (Supersaxo et al. 1990; Lin, 2009). The lymphatic absorption has a linear
correlationwiththepeptidesize(Supersaxoetal.1990).Thisfeaturecanbeexploitedwhen
drugdelivery is targeted to the lymphatic system, for example to the lymphnodes. If the
peptide is absorbed via the lymphatic system, it will also reach the blood circulation, but
significantly slower than when absorbed via capillaries. Hence, the reduced systemic
bioavailability may be partially due to lymphatic clearance and peptide loss may occur
duringlymphatictransportation(PorterandCharman2000;Wangetal.2012).
 Peptide size is not the only factor accounting for varying s.c. bioavailability. Protease
activitywithintheinterstitialspacemightcausepeptidedegradationandlimittheamountof
intact peptides reaching circulation after s.c. delivery (Tang et al. 2004). For example,
erythropoietin has been shown to be degraded in rat s.c. tissue homogenate, but not in
plasma,andpretreatmentoftheinjectionsitewithproteaseinhibitorswasshowntoincrease
insulinplasmaconcentrations(1–5hours)andtoprolongitshypoglycemiceffects(from1to
5 hours) in humans (Takeyama et al. 1991;Wang et al. 2012). In addition, the site of the
injectionhasbeenshowntoaffectabsorption,buttheeffectvariesdependingonlocallymph
andbloodflow,injectiontraumaandphysicochemicalpropertiesofthepeptide(Tangetal.
2004; Lin 2009). Furthermore, body weight may affect s.c. absorption. PEGylated
erythropoietinwas shown to achieve 2fold lower serum concentrations after s.c. injection
intofatrats,comparedwithnormalweightrats,despitethefactthatthedosewasadjustedto
body weight (Wang et al. 2012). The s.c. tissue varies throughout the body and between
individualsandthismayinfluencethepeptideabsorption.Forexample,s.c.insulinhasbeen
shown tobeabsorbed faster fromabdomen (tmax 78.8min,Cmax281pmol/l) comparedwith
thigh (tmax 185min,Cmax 162pmol/l) or upper arm (tmax 192min,Cmax 162) (terBraak et al.
1996). In addition to intrinsic factors, several other factors, such as heat, massage, blood
pressure and movement might affect the conditions of the injection site and hence the




Pulmonary delivery has commanded enormous interest in peptide and macromolecule
deliveryduetothelargeabsorptivesurfacearea,richvascularization,moderatepermeability
and avoidance of first pass metabolism (Tang et al. 2004; Kumar et al. 2006). After the
discoveryofinsulinin1922,thefirstreportsofitspulmonarydeliveryweresoonpublished
(1924–1925) and subsequently its pulmonary administration has been eagerly investigated
(Skyleretal.2001;Antosovaetal.2009).InphaseIIclinicaltrials,inhaledinsulinwasshown
tobeaseffectiveass.c.deliveryandtoachieveevengreaterpatientsatisfaction(Rosenstock
etal. 2004;Skyleret al. 2008).The first commerciallyavailable inhalation insulin (Exubera)
waslaunchedin2006(McMahonandArky2007).However,soonafteritsapproval,Exubera
waswithdrawnfromthemarketin2007duetopoorsales.Someconcernswerealsoraisedby
the possibility of lung function disturbance, variable absorption and the potential for an
increased lung cancer risk among exsmokers (Fountaine et al. 2008;Antosova et al. 2009;
Rosenstocketal.2009).
 Nonetheless,arapidonsetofactioncanbeachievedviapulmonarydelivery(Antosovaet





al. 2004). The absorption of 1–500 kDa macromolecules from lungs is believed to be a
partially sizedependent transport across the alveolar epithelium by passive diffusion.
Peptideswithasmallermolecularweightdiffusefasterthanlargercompounds(Patton1996).
In addition to paracellular absorption, macromolecules can reach the circulation after
transcytosis(Patton1996;Antosovaetal.2009).Thebioavailabilityafterpulmonarydelivery
remainsoften<100%andvariesdependingonthecompound,forexamplebeing12–14%,35–
60%and<30% forpeptideYY336 (Mw4050g/mol), heparin (Mw12000–15000g/mol) and
leuprolide (Mw 1209 g/mol), respectively, despite the high absorptive surface area and the
lowerproteaseactivityinlungswhencomparedwithgastrointestinaltract(Adjeietal.1992;
Qi et al. 2004; Nadkarni et al. 2011). However, the lungs are a very sensitive organ and
susceptibletoirritation.Therefore,localeffectsofthecompoundsonthelungtissueneedto




Similar to the pulmonary route, intranasal delivery could offer a convenient route of
administration and avoidance of firstpass metabolism. The nasal epithelia is highly
permeable allowing rapid absorption of <1–2 kDa molecules, larger molecules will need
absorptionenhancersinordertoachievesufficientbioavailability(Tangetal.2004).Several
peptides or proteins, have been successfully delivered to systemic circulation via nasal
administration,suchasoxytocin(Mw1007g/mol)ordesmopressinacetate(Mw1069g/mol),
whichshowedbioavailabilityof9–34%dependingonthedesmopressinformulation(Fransen
et al. 2009;Gossen et al. 2012). Interestingly, thenasal cavity canbeutilized fordelivering
peptidesdirectlytocentralnervoussystembytargetingtheolfactorybulb(Lawrence2002).
For example, it has been shown that vasoactive intestinal peptide,which cannot cross the
blood brain barrier, and insulinlike growth factor have been successfully delivered to the







g/mol) has been reported to be only one minute, after i.v. bolus, and is due to rapid
degradation caused by dipeptylpeptidase IV (DPPIV) with further elimination via the
kidneys (Cao et al. 2012). Therefore, in order to utilize peptides as pharmaceutical
compounds,itisoftendesirabletomodifytheirpharmacokineticproperties,forexample,to
improve absorption or to prolong their halflife. This can be pursued by 1)modifying the
molecularstructuretomakeitmorestable2)usinginhibitoryagentstopreventdegradation





impurities, drying, agitation and storage, and several of those can be found in the
formulation processes of traditional peptide delivery systems, such as polymer based
formulations(Wang2005;Yeetal.2010; Jiskootetal.2012).Theformulationprocessmight






7.5, storaging 24 h, +5 C; d) PBS, pH 7.5, 24 h storaging at room temperature) and were
administrereds.c.,theonsetofresponse,absorptionrateandbioavailabilitywereinfluenced
bythesizeoftheformedaggregatesduetothedifferentpreparationconditions(Clodfelteret




pose challenges. When calcitonin was investigated in poly(ethylene glycol)terephthalate
(PEGT) and poly(butylene terephthalate) (PBT)matrixes, in order to develop a controlled
releasesystem, incomplete invitro releasewasdependentonthepresenceofsodiuminthe
release medium due to aggregation (van DijkhuizenRadersma et al. 2002). After peroral
calcitonin administration in three different chitosanbased controlled release systems, the
decrease in plasma calcium level was measured in rats (Guggi et al. 2003). However,
althoughallformulationsshowedsustainedreleaseinvitrowithin4hours,invivoonlyoneof
them caused a significant, 10%decrease in calciumplasma levels lasting for 12 hours, the
secondhadaslighteffectandthirdhadnoeffectatallatanequal50gdose.Anintravenous
solutionhad itsmaximaleffect (ca20%decrease)at4hoursafter the injection. Inaddition,
traditionalpolymericpeptideorproteindeliverysystemssufferoftenfromalimitedpayload
capacity,achievinganaveragedrugcontentof7%invariousmicroparticles,andoftenhigh
burst release is followed by varying release profile (Ye et al. 2010). The bioactivity of
lysozyme in biodegradable microspheres was shown to be strongly affected by the
experimentalconditionsduringfabrication,sincebioactivefractionoflysozymevariedfrom
0.3% to38% invitro, regardless theentrapmentefficiency (GhaderiandCarlfors1997).The
optimal kind of controlled release system would be safe, efficient, costefficient and
biodegradableandprovideaprolonged invivo responsebyamoderateburstdrugrelease,
followed by sustained release enabling steady plasma concentrations over an extended
periodoftime.
2.2 APPETITE REGULATION AND PEPTIDES 
Obesity(bodymassindex(BMI)30kg/m2)andoverweight(BMI25kg/m2)areapandemic
health crisis with an extremely high economical costs. According to the World Health
Organization (WHO) more than 1.8 billion adults and over 40 million under 5years old
childrenwere overweight in 2008 and 2010, respectively (WHO 2012). Furthermore, about
500millionof theoverweightareobese,which is currently the fifth leading risk forglobal
deathsandobesityincreasesalsotheincidenceofotherdiseases,suchascancer,diabetesand
ischemicheartdisease (WHO2012). In theEuropeanUnion, the total costsofobesitywere
estimated to be 33 billion € in 2002 (Wang et al. 2011). Therefore, strategies have been
launchedtopreventobesity,andthesedohavenotonlyhealthbenefits for the individuals
butalsoeconomicalconsequencestosociety(Wangetal.2011;WHO2012).Therehavebeen
several, small molecular weight antiobesity drugs on market, but they have had poor
efficacy, tolerability and serious safety issues, mostly related to their side effects in the
cardiovascular and central nervous system. Recently, sibutramine and rimonabant were











2012). Since the elimination halflife of GLP1 is very short after administration (1 min),
synthetic GLP1 analogs with improved stability (exenatide) have been developed and
currentlycommerciallyavailableforthetreatmentoftypeIIdiabetesasdailyandweeklys.c.
injections(Byetta,Bydureon)(Caoetal.2012;EMA:ByettaEPARscientificdiscussion2006).
There are reports that exenatide reduces body weight, stimulates insulin, suppresses
glucagon release and lowers blood glucose (Drucker and Nauck 2006). In addition to
peripheral actions, GLP1 acts centrally having anorexigenic effects (Burcelin et al. 2007).
Cholecystokinin (CCK), which has both peripheral and central actions, is released
postprandially from Icells of small intestine, in response to fat, amino acids and small
peptides and by stimulating PYY release and inhibiting ghrelin it inhibits food intake
(Dockray2009).Thehypothalamusisthecenterinthebraincontrollingfoodintake,sinceit
receives information of the nutritional status from peripheral organs, such as stomach,
intestine and adipose tissue (Fig. 2.1). The mechanisms regulating obesity are a complex




cholecystokinin (CCK), peptide YY (PYY), neuropeptide Y (NPY), leptin and ghrelin have
important roles in thephysiologyof regulating energybalance among theothers, they are





PYY336,whichwere selected due to their different functionmechanisms and availability.
Briefly, GhA abolishes ghrelin induced feeding and MTII is a synthetic analog of 
melanocytestimulatinghormone(MSH)agonistformelanocortinreceptorsinhibitingfood
intake (Asakawa et al. 2003; Hadley andDorr 2006). PYY336 is an anorexigenic cleavage






Figure 2.1. Appetite control consists of several regulatory factors, which are integrated in 
hypothalamus. The simplified scheme (not in scale) presents major peripheral and central signals 




Table 2.2. Description of ghrelin, PYY3-36 and melanocortin -MSH. 





Source Effect Reference 






























various effects  







Ghrelin is cleaved from117 amino acidprecursor into apeptideof 28 amino acids; itwas











been described, including effects on cardiovascular system, reproductive axis, insulin and




be biologically inactive since it does not bind to GHSR1a receptor but it is currently
postulated tohave itsown functions (Pattersonet al. 2005;Verhulst andDepoortere2012).




shown to be dependent on the acylation status of ghrelin and species dependent. Human
ghrelinwasreadilytransportedbyasaturablesysteminabidirectionalmannerthroughthe
BBB,whereas theblood tobrainandbrain tobloodpenetrationofmouseghrelinanddes
octanoylmouse ghrelinwereminimal, respectively in amousemodel (Banks et al. 2002).
Interestingly,elevatedtriglyceridelevelsaswellasfastinghavebeenreportedtoincreasethe
permeabilityofghrelinacrosstheBBB,whereasobesityhadtheoppositeeffect(Banksetal.
2008). Ghrelin can bind to a GPCR, GHSR1a in presynaptic nerveendings, directly
influencingneurotransmitter releaseand the centraldeliveryofghrelinantagonist reduced
the effect of systemic ghrelin administration on food intake (Abizaid et al. 2006). Ghrelin
activates the neuropeptide Y (NPY) and agoutirelated peptide (AgRP) coexpressing
orexigenicneuronsofarcuatenucleus(ARC)inhypothalamus,whichfurtherinfluencesthe
anorexigenic proopiomelanocortin/cocainamphetamine related transcript (POMC/CART)
neurons (Cowley et al. 2003). Since those neurons are intimately involved in controlling
appetite and energy balance, the effect of ghrelin on energy homeostasis is believed to be
mediatedviatheirfunction(Castañedaetal.2010).Insupportofthathypothesis,treatment
with NPY (Y1/5 receptor) and AgRP antagonists and antibodies was able to abolish the




involved inmeal initiation, but cognitive factors may also contribute, as the postprandial
reduction in plasma levels was much stronger in subjects who were anticipating a meal
(Cummingsetal.2001;Callahanetal.2004;Ottetal.2012).InadditiontoNPY/AgRPneuron
activation, orexigenic effects might be mediated via vagus nerve or be direct actions to
mesolimbic reward system (Naleid et al. 2005; Abizaid et al. 2006; Cummings 2006). In





 Bymodifying thedegreeof acylation, the centralorperipheral actionsofghrelin canbe
altered (Heppner et al. 2012). When circulating ghrelin is bound to RNA Spiegelmer
(polyethylene glycolmodified lRNA nucleotide), the ghrelin induced feeding is blocked
withoutaffectingtheeffectofnonpeptideGHSR1aagonistandweightlossispromotedin
mice (Shearman et al. 2006). In addition, ghrelin neutralization by the RNA Spiegelmer
impaired restoration of the body weight after fasting, and affected lipid metabolism by




of BIM28163 antagonizedGHSR1a activation, as it abolishes the ghrelin induced growth
hormone secretion,but surprisingly chronicadministration increases food intakeandbody




might be unknown GHSR subtypes, or desacylated ghrelin might have other effects
(Murphyetal.2006).Theseobservationshighlightthattheghrelinsystemneedstobefurther
investigatedinordertoclarifythemechanismsinvolvedinregulatingfoodintake.
 In addition to a role in short term energy regulation, ghrelin is involved in long term
energybalance.Ghrelinreducedtheamountoffatbeingutilizedasafuel,whichresultedin
weight gain and increased adiposity in rodents (Tschöp et al. 2000). In humans, the
endogenous ghrelin levels are negatively correlatedwith bodyweight and fat content and
respond tochanges inbodyweight, regardlessofwhether theweight loss isdue tocaloric
restrictionorexerciseinduced;thelowerthebodyweight,thehighertheghrelinlevelsand
vice versa (Tschöp et al. 2001; Cummings and Shannon 2003; Cummings 2006). The
postprandial fall in ghrelin levels is absent in obese individuals, although they are still
sensitivetotheactionsofghrelin(Englishetal.2002;Druceetal.2005).Furthermore,thereis
a report that ghrelin levels decrease after bariatric surgery (Camilleri et al. 2009).
Interestingly, in PraderWilli syndrome, which is an autosomal dominant disorder with
symptoms of hyperphagia and morbid obesity, circulating ghrelin levels are significantly
higher than in healthy subjects, but decreasing the ghrelin levels by administration of the
longactingoctreotide for 16weeksdidnot affect theirweight or appetite (DeWaele et al.
2008; Yi et al. 2011). These the mechanisms, which control ghrelin release are not yet
understood(Castañedaetal.2010).
 Due to ghrelin’s role in regulation of both short and long term energy balance, it is
consideredas anattractiveoption for treatingobesity andeatingdisorders (Yi et al. 2011).
GHSR1a receptors have a high constitutive activity and mutations affecting that lead to
obesity(Holstetal.2003;Castañedaetal.2010).Deletionoftheghrelinreceptorandghrelin
hasbeenshownto increasemotoractivityandtoelevateenergyexpenditure(Pflugeretal.
2008). Interestingly, ablation of ghrelin receptorwas shown to improve insulin sensitivity,




mayhavepotential in the treatmentmetabolicdisorders, suchas type IIdiabetes (Verhulst
and Depoortere, 2012). Therefore, efforts have been taken in developing longacting
unacylatedghrelinpeptideanaloguesfors.c.delivery(Julienetal.2012).However,duetothe
wide ranging effects of ghrelin, itmay be challenging to develop an effective drugwhich








The melanocortin system is widely involved in various physiological functions in central
nervous (CNS) and peripheral system including, for example, skin pigmentation,
cardiovascular regulation, renal function, circadian rhythm, inflammation and energy
homeostasis(Marstonetal.2011).Thephysiologicalmelanocortinreceptoragonists,namely
,andmelanocytestimulatinghormones (,andMSH)andadrenocorticotropic
hormone (ACTH139) are derived from proopiomelanocortin (POMC) and bind with
differentaffinitiestofivemelanocortinreceptors(MCR1–5),belongingtoGPCRfamily(Table
2.3) (Marston et al. 2011). The POMC neurons in hypothalamus secrete MSH and the
activationofMC3RandMC4Rinducesanorexigeniceffects.Inaratherunusualsituation,the
MCRs possess both physiological antagonist and inverse agonists, peripheral agouti and
ACTH738andcentralagoutirelatedpeptide(AgRP),respectively(Ollmannetal.1997;Tolle
andLow2008;Bertolini etal. 2009).The receptorshavedownstream targetsaffectingmeal
choice,meal size, satiety and the reward system (Adanet al. 2006;Pandit et al. 2011).The






 MC3RmRNA is expressed in hypothalamus, midbrain and brain stem, but also in the
periphery, e.g. in adipose tissue, heart and pancreas (Ellacott andCone 2006). MSHhas




expression of MC3R is highest in those areas associated with the anorexigenic POMC
neurons, such as ARC and ventromedial hypothalamus, and activation of this receptor
possiblyhavinganautoinhibitoryrolebysuppressingPOMCneuronalactivity(Renquistet
al.2011).Theperipherally(i.p.)administeredMC3RagonistDTrp8MSH(5g)causeda






variantswereshown tobe related to theeatingbehaviors found inobesechildren, suchas
emotionaleatingandlackofenjoymentoffood(Obregonetal.2010).However,theeffectof
variantsonobesityinhumansremainsunclear(Renquistetal.2011).




food intake, inhibit hyperphagia, increase energy expenditure and weight loss and
antagonismhas the opposite effects (Fan et al. 1997; Choi et al. 2003; Schuhler et al. 2003;
Schuhler et al. 2004). MC4R knockout animals have been found to be obese due to
hyperphagia and lowered energy expenditure (Huszar et al. 1997; Adan et al. 2006).
Importantly,asimilarpatterncanbefoundinhumans(Mergenetal.2001).Inhumans,there





2003; LubranoBerthelier et al. 2003; Yeo et al. 2003; Farooqi 2005; Martinelli et al. 2011).
Mutations have also been connected to severe childhood obesity e.g. there is a report that
5.8%of severelyobesechildrencarrymutations inMC4R(Farooqietal. 2003). Inaddition,
POMCgenemutationshavebeendescribedtoleadtoasimilarphenotype(Krudeetal.1998).
 There is clear evidence for a role for melanocortins in energy homeostasis and genetic
obesity, thus this systemhas attracted tremendous interest as a target for obesity therapy.
Different approaches to achieveMC4R agonism have been used, including cyclic peptide
analogues,peptidylstructuresandnonpeptideagonists(Nargundetal.2006).However,the
challenges of targeting themelanocortin systemas an antiobesity target are related to the
many functions of theMCRs,whichmight lead to serious side effects.An MSH analog
MTII,inadditiontodecreasingfoodintake,increasesheartrateandbloodpressureandthe
compoundhasevenbeeninvestigatedforerectiledysfunction(Wessellsetal.2000;Giuliano
et al. 2005; Rinne et al. 2012). Central activation of melanocortin receptors has evoked an
increase in the blood pressure in an obese rat model (do Carmo et al. 2012). Recently,
blockade of MC4R was shown to prevent stresselicited anhedonia (Lim et al. 2012). The






Table 2.3. Melanocortin receptors and their ligands (Modified from Voisey et al. 2003; 















Brain, placenta, gut, 
heart, testis 
Energy homeostasis, sexual 
behavior 
MC4R ACTH, -,-MSH, 
agouti, AgRP 
Brain, adipose tissue Energy homeostasis, erection 
MC5R ACTH, -MSH, 
agouti 
Adrenal gland, adipose 







Figure 2.2. Melanocortins in appetite regulation. POMC: pro-opiomelanocortin; MC3R and MC4R: 
melanocortin receptors in the brain involved in appetite regulation; ---MSH: ---melanocyte 
stimulating hormones, MCR agonists decreasing food intake; AgRP: agouti related peptide, 
inhibits function of MCRs in the brain (Modified from Ducrest et al. 2008).
2.2.3PeptideYYinappetiteregulation
PeptideYY (PYY), belonging topancreaticpolypeptide familywithpancreaticpolypeptide
and neuropeptide Y (NPY), was originally isolated from porcine intestine and later from
human colon (Tatemoto and Mutt 1980; Tatemoto et al. 1988). PYY136 is secreted from
intestinalLcellsandiscleavedbydipeptidylpeptidaseIV(DPPIV)toPYY336,whichisthe
predominant form of circulating PYY (Sam et al. 2012).Meprin , ametalloendopeptidase
abundant on the kidney brushborder membrane, was recently shown to be involved in
degradationofPYY336(Addisonetal.2011).
 ThePYYconcentrationvarieswithin the intestine, increasingfromproximally todistally
andbeingthegreatestintheterminalileumandsigmoidalcolonmucosa(Ballantyne2006).
In addition, PYY is expressed in neurons, especially in peripheral enteric neurons and in
restricted central neurons (Ekblad and Sundler 2002). PYY exerts its central anorexigenic
effects viaNPY receptors and it has been shown to cross the BBB through a nonsaturable
mechanism (Nonaka et al. 2003). PYY136 has a similar affinity towards all the receptor
subtypes,anditstimulatesfoodintake,whereasanorexigenicPYY336hasastrongaffinityto
Y2 receptor but it binds also to Y5 receptor (Keire et al. 2000; Ballantyne 2006). The
anorexigeniceffectofPYY336ismediatedviaactivationofY2receptorsastheeffectcanbe
inhibited by its antagonist BIIE0246 and PYY336 is not effective in Y2 knockout mice
(Batterhametal.2002;Abbottetal.2005b).DeliveryofPYY336 into theARChas induced
dosedependent reduction in food intake (Batterhametal.2002). Inaddition,PYY336may
exert its effects by inhibiting ghrelin activatedneurons inARC (Riediger et al. 2004). Both











Recently, PYY336 has been reported to be present in human andmurine saliva and it is




macronutrient content affects the postprandial PYY release being higher after ingestion of
proteinorfatrichfood(FeinleBissetetal.2005;Batterhametal.2006;Chanetal.2006;Guoet
al.2006;Helouetal.2008;ElKhouryetal.2010).Singlei.p.andcentral(intraARC)injections
ofPYYhavereduced food intake, regardlessof the feedingstatus, in ratsandmice (0.3–10
g), DIO rodent model, in pigs (i.v. 0.25–30 g/kg) and even in humans (0.8 pmol/kg)
(Batterham et al. 2002; Ito et al. 2006; Vrang et al. 2006). Chronic delivery of PYY336, via
repeated i.p. injections,osmoticminipumporasan infusion,hasbeenshown tobeable to
reduce body weight in several species, such as rats and monkeys (Batterham et al. 2002;
Chelikani et al. 2006). In addition to injections, pulmonary delivery of PYY336 has been
shown to be effective in preventing body weight gain in rats (Nadkarni et al. 2011). In
humans,theanorexigeniceffectofPYY336canbedisplayedinobesesubjectsandPYY336
reduces thebrainactivation inresponse to food imagessimilar to feeding (Batterhametal.
2003;DeSilvaetal.2011).
 PYYhas been associatedwith genetic obesity (Ahituv et al. 2006). In Pima Indianmen,
PYY andY2 receptor variants have been linkedwith severe human obesity and a gender




 During the recent years, several investigations of PYY336 as a potential therapeutical
peptidehavebeen carriedout, including clinical trials and evaluation ofdifferentdelivery
systemsaspresentedinTable2.4.PYY336wasshowntobeeffectiveinreducingfoodintake
for4–6h in rats afterpulmonarydelivery,but theabsolutebioavailability remainedunder
15%(Nadkarnietal.2011).After intranasaldeliveryofhighPYY336doses (>600g, t.i.d.)
sideeffects,suchasnausea,dizziness,palpitationsandvomitingwerereported(Gantzetal.
2007). Despite the fact that pharmacologically relevant plasma levels were attained, no
significantdecreaseinbodyweightcouldbeachievedwithlowerdoses(Cmax72.3pM)after
intranasaldeliveryinobesehumansubjectsafter12weeksoftreatmentandthesideeffects
prevented theuseof ahigherdose (Cmax 105.55pM) (Gantzet al. 2007).PYY336 infusions
have been reported to be effective, but they trigger nausea, abdominaldiscomfort andhot
flushes at higher doses and the lower dose did not produce beneficial effects (Sloth et al.






via the per oral route, when combined with an absorption enhancer sodium N[8(2





et al. 2010). PYY336 alone did not decrease total energy intake, butwhen combinedwith
GLP1,themealintakewasreducedby21.5%,butunfortunatelytreatmenthadnoeffecton









 The inconsistency between the PYY336plasma concentrations and energy intakemight
arise fromactivationoforexigenicY1/Y5 receptorswhenhighdoses areused (Gantz et al.
2007). Therefore, increasing the specifity of PYY336 towards the Y2 receptor has been
attempted by modification of the peptide structure by halogen or an amino group
substitutionofthehydroxylgroupofTyr36(Pedersenetal.2009).Blockingthefunctionof
meprinprevents thePYY336degradationandprolongs itseffects inmice,hencemeprin
inhibitorsormeprinresistantanalogscouldimprovePYY336delivery(Addisonetal.2011).
Recently longer acting PYY analogs have been developed. Reversibly PEGylated PYY336
resulted in an eight fold longer functional halflife compared with the natural peptide
(Shechteretal.2005).PEGYlation,using20kDaPEG,resultedin48hlastingeffect(DeCarret
al.2007).Atpresent,aclinicalstudyinImperialCollegeofLondonisrecruitingparticipants























































































































































































































































































































































































































































































































































































































































































































































































































2.3 POROUS SILICON IN DRUG DELIVERY 
Silicon(Si)isamicronutrient,withanaveragedailyintake20–50mgasSiO2,andthehuman
body contains Si 1–2 g but its role in physiology is not completely clear (Panel on
Micronutrients2002;Jugdaohsingh2007;Robberechtetal.2009).Siseemstohavebeneficial
effects, for example, on collagen and glycosaminoglycan formation and therefore, roles in
bone metabolism, wound healing and cardiovascular health have been postulated
(Jugdaohsingh2007;Nielsen2009).ThemajorsourcesofSiarebeverages,grainproductsand
vegetables and no adverse effects have been associatedwith Si occurring naturally in diet
(PanelonMicronutrients2002).TheingestedSiappearsinthecirculationasunboundsilicic
acid (Si(OH)4), and in average 40% of the ingested Si is secreted to urine, with low
reabsorption in kidneys (Popplewell et al. 1998; Jugdaohsingh et al. 2002; Panel on
Micronutrients2002).
 Porous Si (PSi) was originally reported decades ago, while developing a method for
polishing and shaping of Si and germanium surfaces (Uhlir 1956). Canham reported the
photoluminescenceandbioactivepropertiesofPSiinthe1990’s,whichinitializedthecurrent
interest of using PSi in biomedical applications (Canham 1990, 1995). Subsequently, the
potential of PSi micro and nanoparticles has been intensively studied for different






vivo and with peptides/proteins. For a broader view of PSi in drug delivery, more
comprehensivereviewsarerecommended(e.g.Salonenetal.2008,Anglinetal.2008,Serdaet
al.2011,Jarvisetal.2012,Santosetal.2012).
 PSi can be fabricated by dissolving Si wafer electrochemically in hydrofluoric acid
solutions(Fig.2.3),whichenablesgoodcontroloftheporosityandlayerthicknessduringthe
manufacturing process (Salonen et al. 2008). In general, the reactive surface of native PSi
needs to be stabilized prior to usage since, for example, without stabilization PSi may
undergo a side reaction with redoxactive compounds, such as the anticancer drug
daunorubicin (Wu et al. 2011a). The surface stabilizations affect the
hydrophilicity/hydrophobicityand ionicchargeof thePSisurface,butalso todrug loading
andreleaseproperties(Limnelletal.2007;Salonenetal.2008;Jarvisetal.2012).Therefore,a
suitable surface treatment needs to be selected according to the drug of interest and the
desired release behavior. Importantly, especially for sensitive peptidemolecules, the drug
loadingprocedure canbeperformedwithoutusing strong solvents, heat or other stressful
phases,whichoftenexposethepeptidestotheriskofbreakdown(FrokjaerandOtzen2005;
Rathore and Rajan 2008). The extensive surface area of PSi favors achieving high drug
payloads (Fig 2.3), for example, 16.5–53.4% w/w loading degrees were achieved with












andduration,PSisurfacecharge,propertiesof thedrugand loadingsolutioncan influence




Jarvis et al. 2012). In addition to adsorption, the drug can be linked to the PSi surface
covalently (Wuet al. 2008).After administration, the loadeddrug shouldbe released from
PSi either bydiffusingout from thepores (Fig. 2.3) or simultaneously as thePSidissolves
(Vaccarietal.2006;Parketal.2009;Wuetal.2011b).Inaddition,competitiveadsorptionmay
play a role in peptide release, i.e., where a compound present in the releasemedium can
becomeexchangedwiththedrugadsorbedonthecarrier(Guoetal.2009).
Figure 2.3. Schematic example of a porous silicon (PSi) based drug delivery system (not to scale). 
1) PSi is prepared by electrochemical etching and milled into particles with the desired size. 2) 
Drug is loaded into PSi particles by immersing them into a drug solution. 3) Extensive surface 
area of PSi enables achievement of high drug loading degrees. Drug is released from PSi particle 
pores for example via diffusion in release medium. 

 Despite the fact that PSi has been widely studied with small drug molecules, reports
dealingwithpeptidedeliveryarenotthatcommon.Inthefewinvitroinvestigations,proteins
or peptides have been adsorbed onto different PSi surfaces. For example, human serum
albumin (HSA, Mw 67 kDa) was adsorbed on PSi layers and the loading was shown to
increasealmost30foldwith the increasingHSAconcentration(0.001–10mg/ml) incontrast
toplanar Si (Karlsson et al. 2003). In addition to the concentration,pHhas been shown to
affect protein loading. At low concentrations (0.1–1 mg/ml), insulin (pI 5.3) association




concentration at pH 7.4, but at pH 3.8 that remained close to maximum with all the
concentrations (0.1–3.5mg/ml) (Pastor et al. 2011).Themaximum loading capacity (weight
percentageoftheproteininthefinalproduct)of50%insulincouldbeachievedatbothpH
valueswiththehighestinsulinconcentration(3.5mg/ml)oftheloadingsolution.However,
in the case of bovine serum albumin (BSA, pI ~3.9) the situation was different, as the
adsorptionefficiencydecreasedwith increasingBSAconcentrationatpH3.8,but increased













Inadditiontopeptideorprotein loading, fewinvestigationsregarding their invitro release
have been published. The first peptide delivery application was presented, when PSi
microparticles (150–240x24m,20–100nmporedistribution)were shown to improve the
permeabilityofinsulinthroughCaco2cellmembrane(Forakeretal.2003).Invitroreleaseof
papainshowedareducedburstreleasewithincreasedproteinloadinglevel,andtherelease
was further influenced by the surface chemistry of PSi (Prestidge et al. 2007). Recently,





In vivo application of PSi nanoparticles for imaging and carrying an anticancer drug
doxorubicinwasintroducedin2009(Parketal.2009).Amultistagedeliverysystemhasalso
beendeveloped;itconsistsofstage1PSiparticlesloadedwithstage2nanoparticles,suchas
quantumdots and singlewalled carbonnanotubes (Tasciotti et al. 2008).When the former
wereloadedwithsmallinterferingRNAagainstEphA2oncoproteincarryingnanoliposomes,
asustainedgenesilencingperiodfor3weekwasachievedinmiceafteri.v.delivery(Tanaka
et al. 2010b). Recently, the PSi multistage delivery system was applied for breast cancer
therapy, using (3aminopropyl)triethoxysilane(APTES) modified PSi nanovectors loaded




poorly soluble drugs, as their dissolution can be improved by PSi (Salonen et al. 2005;
Heikkiläetal.2007).Inrats,theabsorptionofindomethacinwasshowntobeenhancedafter
itsoraldeliveryinthermallyoxidizedPSimicroparticles(13.6m,poresize<10nm,loading
level 5.6%)asplasma tmaxwas reduced (from2 to0.56h),Cmax andabsolutebioavailability
wereincreasedfrom3.49to6.46g/mlandfrom77.43to100%respectively,comparedwith
commerciallyavailableindomethacinproduct(Wangetal.2010).Inordertoimprovetheper
oral drug delivery, mucoadhesive and gastroretentive properties were generated by
hydrophobin II functionalization of thermally hydrocarbonized PSi (THCPSi), which
decelerated theirpassage throughthegastrointestinal tract,due togastric retentionup to3






hours and were readily cleared from circulation into liver and spleen after i.v. delivery
(Bimbo et al. 2010). PSi surface and itsmodifications affect the binding of serumproteins,
which furthercan influence thebiodistributionof theparticles,especiallyafter i.v.delivery
(Serdaetal.2010;Sarparantaetal.2011;Serdaetal.2011).HydrophobinIIcoatingofTHCPSi
nanoparticles influenced the livertospleen ratio and decreased lung accumulation when
compared with 18FTHCPSi without coating (Sarparanta et al. 2011). THCPSi nanoparticles
wereshowntoalterthebiodistributionofIGF1inrats,astheloadedparticleswereshownto
accumulateextensively intokidney, liverandspleen in20mins,but theywere in liverstill
after4hours,whereasfreeIGF1wasmainlyfoundinthekidney(Huhtalaetal.2012).PSi
hasalsobeeninvestigatedfordeliveryofvaccines,asthedeliveryofthepathogenassociated
molecular pattern presenting vehicle in mice was reported recently by utilizing APTES
modifiedPSiparticles(particlesize1m,porediameter50nm)(Merazetal.2012).
 TheinteractionsbetweendrugandPSisurfaceshavenotbeenthoroughlyevaluated,but
their importance for drug loading and release has been appreciated. Currently, the
adsorptionandinteractionsbetweendifferentbiomoleculesandmesoporoussilicahavebeen
investigated furtherand the informationmaybeexploited toPSi ingeneral. Inaddition to
previously mentioned factors, ionic strength, pore volume, pI and surface charge of the




affect the protein structure due to hydrophobic interactions (Jarvis et al. 2010). Thermal
oxidation of PSi decreased the loading degree, and although it did not alter the native
structuresofrigidlysozymeandpapain,thatofHSAwaslostduetoitssimilarchargewith
theoxidizedPSiandstructuralrearrangement(Jarvisetal.2010).Asaresult,aftercontacting
unoxidized PSi, the bioactivity of lysozyme was less than 20%, due to hydrophobic
interactions,whereas thermal oxidation increased the bioactivity to over 60% (Jarvis et al.






The dissolution rate of PSi increaseswith porosity and is further improved by higher pH
values and temperature (Anderson et al. 2003). In addition, the surface chemistry of PSi
affects the degradation rate and can be further modified. The residence time of PSi
microparticles(ca15–30m),withvariablesurfacechemistries(unmodified,hydrosilylated,
oxidized) varied from 4weeks to 12months in vivo (Cheng et al. 2008). PEGylation (PEG







Invivo, thePSiparticlesandmembraneshavebeenshown tobebiocompatiblewith rabbit
andrateye,respectively(Chengetal.2008;Lowetal.2009).Singleandrepeatedi.v.delivery
ofstage1PSiparticlesdidnotcauseanysignificantchangesinplasmacytokinelevels,renal
or hepatic biomarkers nor did it induce leukocyte infiltration into any investigated tissue




(from 0.5–2 h to 10 days) and chronic (up to 6months) tissue responses after delivery of





standardized experiments,making the resultsdifficult to compare. In addition, the in vitro
setupsdonotprovidefullpictureofthebodyreactionemphasizingtheimportanceofinvivo





been published. According to the current information, PSi appears to be potential,
biodegradable and biocompaticle material for drug delivery, with low toxic properties.
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Ingeneral, theobjectiveof thepresentstudywasto investigate, ifmesoporoussilicon(PSi)
would be suitable to be used as a peptide delivery system.More precisely, how does the






























GhA)was used as amodel peptide. The effects of GhAloaded THCPSimicroparticles on
foodintake(s.c.,GhAdose14mg/kg)andonbloodpressure(s.c.,GhAdose4mg/kg)were
examinedinmiceandrats,respectively.Inaddition,theeffectsofTHCPSimicroparticles(2
mg) on cytokine secretion in mice after single s.c. administration were examined by
determining several cytokine plasma concentrations. The present results demonstrate that
GhAcanbeloadedintoTHCPSimicroparticleswithahighloadingdegree(20%w/w).GhA
loaded THCPSi microparticles inhibited food intake for a prolonged time, and increased
bloodpressuremore slowly than encounteredwith aGhA solution. Furthermore, THCPSi

























1AdaptedwithpermissionofElsevier from:KilpeläinenM,Riikonen J,VlasovaMA,HuotariA,LehtoVP,Salonen J,







systems, such as microspheres, liposomes and cyclodextrins, made of both synthetic and
natural materials, as described earlier. However, many of these systems suffer distinct
limitations.Forexample, theymayhaverelativelysmall loadingdegrees,varyingfromless
than1to5%w/wdependingonthedrugmolecules,carriermaterialsandloadingprocedure
used (Witschi and Doelker, 1998; Redhead et al. 2001; Jain et al. 2008; Yin et al. 2008).






with small molecules, compared with the materials traditionally used in particulate drug
deliverysystemsappearstobeoneofthemostprominentadvantagesofmesoporoussilicon
particles (Salonen et al. 2005). In the previous studies, siliconbased materials have been
claimedtobebiocompatibleandtohavelowtoxicity(Bowditchetal.1999;Rosengrenetal.
2002;Alvarezetal.2009;Parketal.2009).However,fewinvivostudieshavebeenconducted
usingmesoporous silicon based drug delivery systems (Bowditch et al. 1999; Cheng et al.
2008;Salonenetal. 2008;Parketal. 2009), andas farasweareaware thereareno reports
examiningpeptidedeliverywithmesoporoussiliconinvivo.





inarterialpressure (Asakawaetal.2003;Vlasovaetal.2009).The inhibitionof food intake
and the elevation of blood pressure due to GhA administered via THCPSi microparticles
were evaluated as a function of time (0–24 h) in consciousmice and rats, respectively. In
addition,plasmacytokineconcentrationsweredeterminedafterasingleadministration(s.c.)
ofTHCPSimicroparticles (38–53m) inorder toexaminewhether therehadbeenanacute
immunogenicreaction.
4.2 MATERIALS AND METHODS 
4.2.1Materials
Ghrelin antagonist (DLys3GHRP6, HHisDTrpDLysTrpDPheLysNH2) was
purchasedfromPeptidesInternationalInc.(Kentucky,USA).Thesiliconwaferswerebought
from Cemat Silicon S.A. (Warsaw, Poland). Ethanol (99.5%) was purchased from Altia
(Helsinki,Finland).Hydrofluoricacid (HF) (37%–39%)andmethanolwerepurchased from
MerckKGaA(Darmstadt,Germany).Thenitrogen(99.999%)andtheacetylene(99.6%)gases











terminationand then theyweredried in 65 °C for 1h.Thermalhydrocarbonizationof the
microparticleswas done under 1:1N2 : Acetylene flow at 500 °C for 15min as described
earlier(Salonenetal.2004).Theporevolume,averageporediameterandspecificsurfacearea
of the THCPSi microparticles were calculated from desorption branch of the nitrogen
sorptionmeasurements (Tristar 3000,Micromeritics) according toBJHtheory (Barrett et al.
1951).Thesevaluesshowedaverageporediametersvaryingfrom11.8nmto15.6nm,specific
surface areas between 401m2/g and 444m2/g and pore volumes from 0.94 cm3/g to 1.36
cm3/g.
 Three batches of THCPSiwere loaded separately. GhAwas dissolved inmethanol and
mesoporousTHCPSimicroparticlesweresoakedinthepeptidesolutionfor1.5hoursatroom
temperature. The loading solutionwas treatedwith ultrasound 3 times during loading to
ensurehomogenousloading.Theparticleswerefilteredfromthesolutionanddriedfor4hat
room temperature. The loading degreewas determined by thermogravimetric analysis (20
°C/min,25 °C–800 °CN2gaspurge200ml/min,TGA7,PerkinElmer) (Lehtoetal.2005).
Peptideloadingdegreesofthebatchesvariedfrom15.5%to22.0%(w/w).
4.2.3Animals
Male Wistar rats and Balb/c x DBA2 (CD2F1) hybrid male mice were purchased from
National LaboratoryAnimal Center (Kuopio, Finland) at the age of 78weeks. Theywere
housedindividuallyinaregulatedenvironment;temperature22±1°C,relativeairhumidity






Mice were acclimatized to conditions similar to the experiment for 7 days and fasted
overnight(16h)beforethemeasurements.Alltheinjectionsweregivensubcutaneouslyina
volume of 300 l with the dose of GhA being 14 mg/kg. The administered THCPSi
microparticlemasseswere 1.40–1.89mg, depending on theGhA loading degree. To avoid
rapidparticlesedimentationduringthe injection, theviscosityof thevehiclesolution (0.9%
NaCl) was increased by addition of 0.5% CMC. Mice were divided into four different
treatmentgroups:1)vehicle(0.5%CMCin0.9%NaCl),2)unloadedTHCPSimicroparticles
suspended in the vehicle (THCPSi), 3) GhA loaded THCPSi microparticles suspended in
vehicle (THCPSi+GhA) and 4) GhA dissolved in vehicle (GhA). Food was available ad
libitumimmediatelyafterinjectionsandtheeffectsofthetreatmentsonfoodintakeinmice
werestudiedasa functionof timeandmeasuredeveryminute for thenext24husing the
LabMaster®system(TSESystems,Germany).
4.2.5Bloodpressureexperiments
For the implantation of the telemetry transmitters, rats were anesthetized with fentanyl
citrate/fluanisone/midazolam combination (0.158 mg/5 mg/2.5 mg/kg, s.c.). In addition,
buprenorfine(0.05mg/kg,s.c.)andsulphamethoxazole/trimethoprin(0.1mg/kg/0.01mg/kg,
s.c.)wereadministered to theoperatedanimals.Bloodpressure transmitters (PAC40,DSI,
St.Paul,MN,USA)were implanted into theabdominalaorta.Ratswereallowedtorecover
for 7days after surgery andbefore the experiments theywerehabituated tohandling and
injections (s.c). To avoid rapid particle sedimentation while injecting, the viscosity of the
vehiclesolution(0.9%NaCl)wasincreasedbyadditionof0.5%CMC.Theratsweredivided






GhA loading degree. The effects of the treatments on blood pressure were studied as a
functionoftime.Bloodpressurewasmeasuredeachminute,starting7hbeforetheinjections
toobtainabaselineandcontinued for24hafter the treatment.Telemetryreceivers (model





cytokine activity, 2 mg of heat sterilized THCPSi microparticles were injected in 300 l
volume of 0.9%NaCl to 8weeks oldCD2F1mice. The THCPSi dosewas chosen to be in
accordancewiththeparticlemassesusedinthefoodintakeexperiments.LPSwasusedasa
positivecontrol.Controlgroupsreceivedeither300lsalineorLPS(2g/kgin0.9%NaCl,
s.c.). Blood sampleswere collected from saphenous vein 1, 3 and 6 h after treatment. The
concentrationsofseveralcytokines(IL1, IL1, IL2,IL4, IL6, IL10, IL12,MIP1,MIP
1,TNFandIFN)inplasmaweremeasuredusingBioPlexMouseCytokinePanelwith
BioPlex instrument, based on Luminex xMAP technology following the manufacturer	s
instructions(BioPlex®,BioRadLaboratoriesInc.).
4.2.7Statisticalanalysis
Data from the food intakeandcytokine releaseexperimentswereanalyzedusing twoway
Anova for repeated measurements and Bonferroni posttest (GraphPadPrism 4.03 For
Windows, GraphPad Software Inc., San Diego, CA). Results from the blood pressure
experiments were analyzed using KruskalWallis test, followed by pairwise comparisons





No significant differences in food intake could be distinguished between the vehicle (n=6)
andunloadedTHCPSi(n=5)groupsthroughoutthetotal24hfollowuptimeaftercompound
administration. When compared with the vehicle, both formulations GhA (n=5) and
THCPSi+GhA(n=10)(GhAdose14mg/kg),inhibitedfoodintakebutonlytheTHCPSi+GhA
resultedinaprolongeddurationofaction(Fig.4.1).
 During the firsthour after treatment,GhAsignificantly suppressed food intake inmice,





THCPSi+GhA group was lacking this phenomenon (Fig. 4.1CE). These results indicate a
prolonged duration of action in the case of THCPSi+GhA treatment. During further
measurements, up to 24 h after injections similar values in food intakewere obtained for
GhA,vehicleandTHCPSigroups,indicatingthattheeffectofGhAinvehiclesolutionwasno
longerpresent.However,THCPSi+GhAcontinuedtoinhibitfoodintakebetween6and18h
after administration (Fig.4.1D and E). The greatest differences between THCPSi+GhA and









Figure 4.1.A) and B)GhA (14 mg/kg) suppresses food intake between 10–120 mins in mice when 
administered s.c. either in solution or in THCPSi particles. C) The inhibitory effect on food intake 
of GhA was not present between 4–6 hours after administration in mice. D) Only THCPSi+GhA 
treatment inhibited food consumption from 6 to 12 hours in mice. E) THCPSi+GhA formulation 
showed prolonged inhibition of food intake in mice when compared with GhA solution. */¤p<0.05, 


















GhA formulation (Fig. 4.2). When compared with the vehicle (n=9), unloaded THCPSi
particles (n=9)causedonlyamarginal increase inbloodpressure. Incontrast, the injections
containingGhA (4mg/kg) invehicle solution (n=12) or loaded intoTHCPSimicroparticles
(n=9) increased blood pressure, when comparedwith the vehicle. These effects were seen
already 1 h after administration. The greatest elevations in blood pressure in the GhA in
vehicle group were obtained at 1 h after drug administration, whereas THCPSi+GhA




Figure 4.2. Blood pressure increased after s.c. administration of GhA+THCPSi (dose of GhA 4 




Plasma concentrations of several cytokines were measured 1, 3 and 6 h after s.c.
administrationofunloadedTHCPSimicroparticles(38–53m,74mg/kg).Valuesareshown
in Table 4.1. The cytokine levels after THCPSi (n=6) administration were similar to those
assayedafter0.9%NaClinjections(n=6)atalltheexaminedtimepoints,withoneexception,



















































Table 4.1. THCPSi microparticles (38–53 μm) are not increasing plasma cytokine 




Concentration in plasma, pg/ml (Mean±SEM) 
  NaCl 0.9 % THCPSi LPS 
 IL-1    
1  44±6 61±4 63±6* 
3  36±5 45±6 67±3*** ¤¤ 
6  30±3 50±5+ 58±4*** 
 IL-1    
1  58±9 84±10 106±14 
3  48±5 58±10 257±20*** 
6  49±10 74±17 217±14*** 
 IL-2    
1  27±5 34±3 37±8 
3  29±3 30±6 54±4** ¤¤ 
6  31±5 34±3 60±2*** ¤¤ 
 IL-6    
1  77±14 89±4 2278±281*** ¤¤¤ 
3  141±13 95±19 4128±771*** ¤¤¤ 
6  686±221 404±128 6129±2090*** ¤¤¤ 
 IL-10    
1  66±11 78±4 259±44*** ¤¤¤ 
3  71±13 68±12 235±44*** ¤¤¤ 
6  58±7 84±25 310±31*** ¤¤¤ 
 IL-12    
1  89±12 92±7 122±11 
3  119±17 108±17 2555±558***¤¤¤ 
6  120±19 105±19 1150±96*** ¤¤¤ 
 IFN-    
1  141±23 165±10 157±31 
3  120±27 152±39 237±25 
6  54±10 169±64 190±26 
 TNF-    
1  688±111 735±80 7686±1943*** ¤¤¤ 
3  715±175 752±188 1534±154 
6  545±50 961±332 1199±205 
 MIP-1    
1  104±13 177±69 284±38* 
3  90±20 137±51 709±42*** ¤¤¤ 
6  62±10 182±74 563±26*** ¤¤¤ 
 MIP-1    
1  189±35 230±12 1837±255** ¤¤ 
3  175±35 186±38 5016±863*** ¤¤¤ 






In the present study, the pharmacological activity of GhA administered via THCPSi
microparticlesinvivowasexaminedbymeasuringtwodistinctparameters,foodintakeand
blood pressure. It was noted that, sustained effects on food intake inhibition and blood
pressurewereobtainedwithTHCPSi+GhAmicroparticles.Inthefoodintakeexperiment,the
effectofGhAreleasedfromTHCPSioverlappedwiththeeffectofGhAinvehicleinjections
between 4 and 6 h. THCPSi+GhA showed greater inhibition in food intake than GhA in
vehiclefromthe6htimepointwiththeeffectlastinguntil18haftertreatment(Fig.4.1Dand
E).Themaximumchanges inbloodpressurewereobservedafter1and4hGhAinvehicle




enables obtaining high loading degrees, and loading of heatsensitive molecules, such as
peptides,atroomtemperature.ExposureofPSidrugdeliverysystemtoasolventactivates
the drug release. In the present study, thermal hydrocarbonizationwas used as a surface
modificationduetoitsadvantageousproperties.Hydrocarbonizedsurfaceisrelativelystable
when compared with the native hydrogen terminated surface of PSi, which oxidizes
spontaneously at room temperature (Salonen et al. 2004). Stabilization of the PSi surface
allowsprolonged storage of the particles and their use formore sensitive drugmolecules.
Basedonthepreliminarystudies,bothnativePSisurfacewithhydrogenterminatedsurface
andthermallyoxidizedPSi,werefoundtoreactwithGhA.
 Despite the stability of THCPSi in ambient conditions, THCPSi microparticles are
biodegradable, which is an important character for a drug delivery material. Different
propertiesofPSi,suchasporosity,alterthedegradationrate(Andersonetal.2003).Native
PSi,iseliminatedfromthebodyviakidneysasorthosilicicacidrelativelyfast,in1–4weeks
when administered intravenously as nanoparticles (Park et al. 2009). The degradation of
THCPSimicroparticlesisslowerthanthatofnativePSi.Inourpreliminarystudies,2mgof
THCPSi microparticles (38–53 m) were observed to degrade gradually in 4 weeks after
subcutaneousadministrationinvivo(Fig.4.3,unpublisheddata).
 Before one can safely use THCPSi for drug delivery, it is essential to examine the
inflammatoryandtoxiceffectsofthematerial.However,onecommonlyusedinvitrotoxicity
testhasbeenreportedtobeunsuitableforusewithporoussiliconmicroparticlesduetothe
spontaneous redox reactions between MTT (3[4,5dimethylthiazol2yl]2,5
diphenyltetrazolium bromide) and PSi particle surface (Laaksonen et al. 2007). Therefore,
plasma cytokine concentrations after single subcutaneous administration of unloaded
THCPSimicroparticles(38–53m)weremeasuredinmice.Cytokinesaregroupofsignalling
moleculesandapartoftheimmunesystem.Theirappearanceisinvolvedininfectionsand
inflammatory conditions, defending the body against microbes and other foreign bodies.
Introductionofforeignmaterial,suchasdrugcarriers,toaphysiologicalsystemcaninduce
cytokineactivitybecauseofcausinginflammatoryreaction(Choetal.2007;Andersonetal.
2008;Rodriguez et al. 2009). In thepresent study,THCPSi administrationdidnot increase
plasma cytokine concentrations significantly when compared with the 0.9% NaCl
administration (Table 4.1). The only significant increase after THCPSi administration was
observed in IL1 at 6 h after particle administration, suggesting possible slight tissue








2008). Moreover, recently published in vivo data indicates that PSi appears to be a safe
materialforintravitreal(Chengetal.2008)andintravenous(Parketal.2009)administration.

Figure 4.3. Visual observation of the subcutaneous injection site after 1 day (left) and 4 weeks 
(right) administration of THCPSi microparticles (2 mg). 
4.5 CONCLUSION 
In conclusion, themodel peptide,GhA,was successfully loaded intomesoporous THCPSi
microparticles(38–53m)withahighloadingdegree,asmuchas20%w/w,andthepeptide
remainedpharmacologically active after the loading procedure. In vivo the peptide loaded
microparticlesshowedaprolongedeffectcomparedwiththepeptidesolution.Theseresults
suggestthatthepeptidewasreleasedfromtheparticlesinacontrolledmannerafteritss.c.
administration. In addition, a single administration of the THCPSi microparticles did not
acutely change plasma cytokine concentrations, suggesting THCPSi could represent a
suitablematerialfordrugdelivery.Thesefindingsareencouragingthoughfurtherstudiesof





























determine if nanostructured porous silicon could sustain the release and prolong the
duration of action of a model peptide melanotan II (MTII). Thermally hydrocarbonized
nanoporous silicon (THCPSi)microparticles (38–53 m)were loadedwithMTII. The pore






and the effect lasted 1 h longer. In addition, MTII loaded THCPSi changed the water
consumption after 150 min, when the immediate effect of MTII solution was already
























2Adaptedwith permission of Elsevier from:KilpeläinenM,Mönkäre J, VlasovaM,Riikonen J, LehtoVP, Salonen J,
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prolong the presence of the active molecule in blood circulation, leading to lower
administrationfrequencyandbetterpatientcompliance.
 Porousmaterialshavebeenusedoveradecade in tissueengineeringanddrugdelivery.
The extensive adsorbing surface area of PSi has the potential to carry and deliver large
amountsofdrugmoleculeswithinarelativelysmallcarriermaterialmass(Fig.5.1)(Salonen
etal.2005;Salonenetal.2008).Typicallydrugisentrappedindrugcarriersusingmethods
with several different stages before reaching the final formulation, which might cause
degradationor lossofbioactivityof thedrugduring thepreparation (Witschi andDoelker
1998;AlmeidaandSouto2007;Antonetal.2008;Rawatetal.2008).Onthecontrary,ontoPSi






obesity, erectile dysfunction and inflammation (Voisey et al. 2003; Hadley andDorr 2006;
Bertolini et al. 2009). Melanotan II (MTII) is a potent, unselective peptide agonist for
melanocortin receptors and the pharmacological actions of MTII include inhibition of
drinkingandelevatedheartrate(Murphyetal.2000;Nietal.2006).
 The aim of the present studywas to investigate in vitro and in vivo whether thermally
hydrocarbonized (THCPSi) microparticles could serve as a sustained release system for
peptides.THCPSimicroparticles(sizefraction38–53m)wereloadedwithasyntheticmodel
peptide,melanotan II (MTII).Theporediameter,volume, specific surfaceareaand loading
degree of the THCPSi microparticles were analyzed and the release of the MTII was
examined in vitro. Furthermore, the duration of the action of MTII delivered via THCPSi






Figure 5.1. Cross section of nanoporous silicon and polymer drug carriers. The scheme is not in 
scale.
5.2 MATERIALS AND METHODS 
5.2.1Reagents
MTII (AcNlecyclo [AspHisDPheArgTrpLys]NH2, Mw 1024.2) was purchased from
Peptides International Inc. (Kentucky, USA). The silicon wafers were bought from Cemat
SiliconS.A.(Warsaw,Poland).Ethanol(99.5%)waspurchasedfromAltia(Helsinki,Finland).
Hydrofluoricacid (HF) (37%–39%)was suppliedbyMerckKGaA (Darmstadt,Germany).
Methanol forpeptide loadingwas obtained fromMerckKGaA (Darmstadt,Germany) and
for invitroexperimentsfromJTBaker(Deventer,TheNetherlands).Thenitrogen(99.999%)
and the acetylene (99.6%) gases were purchased from AGA (Espoo, Finland).
Carboxymethylcellulosesodium(CMC)wasboughtfromSigmaAldrichChemie(Germany).
HPLC reagents were acetonitrile (HPLC grade, JT Baker, Deventer, The Netherlands),




1.4 g disodium hydrogen phosphate (Merck KGaA, Darmstadt, Germany) and 0.2 g
potassium dihydrogen phosphate (Merck KGaA, Darmstadt, Germany) in 1000 ml of
deionized water. In addition, bovine serum albumin (BSA, SigmaAldrich, St. Louis, MO,





fraction.After thedrysieving, theparticleswerewashedona38msievewithethanol in









The pore volume, average pore diameter and specific surface area of the THCPSi
microparticles were calculated from desorption branch of the nitrogen sorption





release experiments. MTII was dissolved in methanol and the mesoporous THCPSi
microparticles were immersed in the peptide solution (37 mg/ml) for 1.5 h at room
temperature.Theloadingsolutionwastreatedwithultrasound3timesduringtheloadingto
ensurehomogeneity.Theparticleswerefilteredfromthesolutionanddriedfor3hatroom
temperatureadditional 30min invacuum.Thepeptide loadingdegreewasdeterminedby
thermogravimetric(TG)analysis(20°C/min,25°C–800°CN2gaspurge200ml/min,TGA7,
PerkinElmer) as described earlier (Lehto et al. 2005). Peptide loading degrees of the two
batcheswere14.8±0.3%and15.1±1.4%(w/w)asmeasuredbyTG. Inaddition to theTG
analysis,theloadingdegreeofthesecondbatchwasanalyzedwithHPLCtobe15.3±2.0%
according to methanol extraction. The MTII particles were washed 5 times with 1 ml
methanol, and the concentration of MTII in methanol extract was analyzed by high
performanceliquidchromatography(HPLC)asdescribedinsection5.2.4.
5.2.3Invitrorelease
MTII loaded microparticles (2 mg THCPSi, containing 302 g MTII) were placed in




Fresco,Osterode,Germany) and supernatantswere collected for theHPLC analysis of the
MTIIconcentration.ThemicroparticleswereresuspendedinfreshpH7.4PBSbuffer(+37°C,







diffusional squarerootoftimerelease,a slopebetween0.5and1.0 indicatesananomalous
transport,andaslopeof1indicateszeroorderreleasekinetics(CostaandLobo2001).
5.2.4HighPerformanceLiquidChromatographyanalysisofMTII
MTII was analyzed with a Gilson High Performance Liquid Chromatograph. The system
consisted of anUV detector (UV/VIS151), pump (321), autoinjector (234), interface (506C)
andintegrator(Unipoint3.0).Themobilephasewasamixtureofacetonitrile(36%v/v),water
(64%v/v),trifluoroaceticacid(0.1%v/v)andtriethylamine(0.15%v/v).Theprecolumnwasa
reversephase Pelliguard® LC18 column (20 x 4.6 mm id, particle size 40 m, Supelco,
Bellefonte,PA,USA)andtheanalyticalcolumnwasareversephaseSupelcosil®C18column
(150 × 4.6mm id, particle size 5m, Supelco, Bellefonte, PA,USA). Sampleswerediluted
appropriately with the mobile solutions before their injection into the HPLC system. The







Male Wistar rats and Balb/c x DBA2 hybrid male mice were purchased from National








Telemetry transmitters for monitoring the heart rate were implanted as described earlier
(Vlasova et al. 2009). Before the experiments, the rats were familiarized to the treatment
procedure, inordertoavoidstress inducedbloodpressure increase.All the injectionswere
given subcutaneously in a volume of 700 l. The dose of MTII was 3 mg/kg and the
administered THCPSi microparticle mass was 20.3 mg/kg. To facilitate the injection
procedure, the vehicle viscosity (0.9% NaCl) was increased by addition of 5 mg/ml
carboxymethylcellulosesodium(CMC).
 Ratsweredividedintofourdifferenttreatmentgroups:(1)vehicle(5mg/mlCMCin0.9%
NaCl) (n=6), (2)unloadedTHCPSimicroparticles suspended in thevehicle (THCPSi) (n=6),
(3)MTII loadedTHCPSimicroparticles suspended in thevehicle (THCPSi+MTII) (n=6)and
(4) MTII dissolved in the vehicle (MTII) (n=6). Telemetry receivers (model RPC1) were
placedunderindividualcagesfordataacquisitionwithAquisitionA.R.T.software(DSI,MN,





into four different treatment groups: (1) vehicle (5 mg/ml CMC in 0.9% NaCl) (n=5), (2)











The MTII release from THCPSi microparticles (loading degree 15.1% w/w) clearly
demonstratedthesustainedrelease,withamoderateburstreleaseduringthefirst30minsin








until 8 daysMTII release from the THCPSimicroparticles followed closely squarerootof
timekinetics (n= 0.517 ± 0.001,mean±SEM,n=4).The release rate constantwas 13.7%/d½
(mean/SEM,n=4).

Figure 5.2. Melanotan II in vitro release from THCPSi microparticles (38–53 μm, loading degree 
15.1% w/w, 1.3 mg/ml) in PBS, pH 7.4 (37 °C).  
5.3.2InvivoeffectsofMTII
5.3.2.1Heartratechangesinrats
The rats receivedoneof the following treatments;MTII loadedparticles (THCPSi +MTII),
unloaded particles (THCPSi), vehicle or MTII solution (more detailed description of the
treatments in thematerialsandmethods section).Fig.5.3 shows theeffectsof thedifferent
treatments on heart rate in rats as a function of time. The heart rate baseline before the
treatments was 350.9 ± 13.4 beats per minute (bpm), which is in agreement with earlier
studies(deMenezesetal.2008;Vlasovaetal.2009).Subcutaneousinjectionsofpeptidefree
vehicleevokedatransientincreaseintheheartrate(45.6±6.2bpm),whichnormalizedtothe
baseline 1 h after the injections. This temporary effect, due to the treatment protocol, is in
accordancewith the results from other groups (Sharp et al. 2005). A similar reactionwas
observed after injection of unloadedmicroparticles in the vehicle (THCPSi).MTII solution
treatment caused an immediate and significant increase in the heart rate and the effect of
MTIIlastedfor7haftertheinjections.Onthecontrary,microparticlesloadedwithMTIIdid
notevokeanimmediateincreaseintheheartrate,butchangedthecurveprofile.Insteadof
the immediate effect, the THCPSi+MTII treatment showed a delayed and sustained
increasing effect on theheart rate, starting at 2 h after the treatments.AfterTHCPSi+MTII
injections, the heart rate increased until 6 h after the treatments and then decreased
gradually, reachingasimilarbaselineof theheartrateas theothergroupsat12hafter the
injections.Themaximal increasesof theheartratewereobservedat3hand6hafterMTII
and THCPSi+MTII injections, respectively. In addition, the heart rate stayed elevated 1 h
longer period after THCPSi+MTII treatment when compared with the MTII injections.
Therefore, thepresent results showthat theTHCPSi+MTII treatmentcausedadelayedand





Figure 5.3. The change in the heart rate is delayed after THCPSi + MTII treatment when 
compared with MTII treatment in rats (MTII dose 3 mg/kg, s.c.). Treatments: Vehicle = 5 mg/ml 
CMC in 0.9% NaCl, THCPSi = unloaded THCPSi microparticles suspended in the vehicle, THCPSi + 
MTII = MTII loaded THCPSi microparticles suspended in the vehicle; MTII = MTII dissolved in the 
vehicle. Data are presented as mean ± SEM, (n = 6), #p < 0.05, ##p < 0.01 THCPSi + MTII vs. 
vehicle; *p < 0.05, **p < 0.01 MTII vs. vehicle. 

5.3.2.2Waterconsumptionchangesinmice
Themicewere treatedwith similar formulations to rats and theirwater consumptionwas
measured for 24 h.When comparedwith the vehicle,MTII andTHCPSi +MTII tended to
inhibitwaterconsumption,butdidnotreachstatisticalsignificance.However,adelayedand
prolongedeffectwasachievedonlywiththeTHCPSi+MTIItreatment,indicatingsustained





On the contrary, at 210min after the injections, the totalwater consumptionwas lower in
THCPSi+MTIIgroupwhencomparedwiththeothers(Fig.5.5).TheTHCPSi+MTIItreated












Figure 5.4. Cumulative water intake in mice. The inhibition in water consumption tends to be 
delayed and prolonged in THCPSi + MTII group when compared with MTII treatment. (MTII dose 
3.7 mg/kg, s.c.) Treatments: Vehicle = 5 mg/ml CMC in 0.9% NaCl, THCPSi = unloaded THCPSi 
microparticles suspended in the vehicle, THCPSi + MTII = MTII loaded THCPSi microparticles 
suspended in the vehicle; MTII = MTII dissolved in the vehicle. Data are presented as mean ± 
SEM, n = 6, except vehicle n = 5. 

Figure 5.5. Total water intake at time 210 min after treatments in mice. The effect of THCPSi + 
MTII is present, while that of MTII has declined. Treatments: Vehicle = 5 mg/ml CMC in 0.9% 
NaCl, THCPSi = unloaded THCPSi microparticles suspended in the vehicle, THCPSi + MTII = MTII 
loaded THCPSi microparticles suspended in the vehicle; MTII = MTII dissolved in the vehicle. Data 




release of an activemodel peptide from the THCPSimicroparticles,which is indicated by
delayedandprolongedeffectsofMTIIwhendeliveredinthenanostructuredPSi.Inrats,the




THCPSi +MTII treatmentwhen comparedwith theMTII treatment (Fig 5.3). In addition,





theMTII release was faster in vivo than in vitro. The changes in the heart rate andwater
consumption could be observed until 11 and 5 h in rats andmice, respectively, after the
THCPSi+MTII treatments,when the effects ofMTII solutionwere not anymore detectable.
After12h,only20%oftheloadedMTIIwasreleasedinvitro(Fig.5.2)buttheinvivoeffects
werealready finished (Fig.5.3–5.5).However,20%releaseof the loadedMTII invivo, from
theadministeredTHCPSi+MTIItreatmentduring12hours,wouldnothavebeensufficientto
produce theobserved responses. Inanearlierpublication (Kilpeläinenetal. 2009)wehave
studiedinvivopeptide(ghrelinantagonist)deliveryviaPSibutasfarasweareaware,there
arenootherstudiesreportinginvivopeptidedeliveryusingPSiasasustainedreleasesystem.
 Silicon isacompound,which isapartofoureverydaydietandPSi isconsideredtobe








 Peptides are very promising molecules for the treatment of many severe illnesses, but
unfortunately they typically cannot be compressed to tablets and administered per orally
withagoodbioavailability.Therefore,themicrometerdrugcarriersmightofferasolutionto
theobstaclesofpeptideadministration.Inthepresentstudy,ahighpeptideloadingdegree
was obtained (15%w/w). Nanoporous structure and large surface area of PSi has a great
capability to adsorbanddeliverhighamountsof thepeptidemolecules,whichhasbeena
problemwiththetraditionalpolymermaterials(Fig.5.1).
 Inconclusion, thepresent invitro experimentdemonstratedsustainedMTII release from
the nanoporous THCPSi microparticles (38–53 m). In agreement, in vivo experiments
revealeddelayedandprolongedeffectsofMTII,i.e.prolongedincreaseoftheheartrateand
decreaseofthewaterconsumptioninratsandinmice,respectively,whenadministeredvia
THCPSimicroparticles.Therefore, these results clearly indicate thatTHCPSimicroparticles
have a capability to sustain the release of active peptides and thus to prolong their
pharmacological effects in vivo. In addition, controllable porosity, tunable surface














Purpose: To achieve sustained peptide delivery viamesoporous silicon (PSi)microparticles
and to evaluate the effects of different surface chemistries on peptide YY336 (PYY336)
delivery.








loadedPYY336was released fromTOPSi, THCPSi andUnTHCPSi, respectively.Absolute
PYY336bioavailabilitieswere98,13,9and38%whendeliveredsubcutaneously inTOPSi,
THCPSi, UnTHCPSi and solution, respectively. The results clearly demonstrate improved



























Native PSi is unstable and is therefore typically stabilized and depending on the type of
application,thePSisurfacecanbefurthermodified.Contactanglesofoxidized,undecylenic
acid treated and carbonized PSi have been reported to be <6°, 60° and >90°, respectively
(Björkqvistetal.2004;Alvarezetal.2009).Hence,partialoxidationofPSi(thermallyoxidized
PSi,TOPSi)surfaceundermildtemperaturesproducesahydrophilicsurfacewithmoderate
stability, whereas thermal hydrocarbonization of PSi creates more stable, hydrophobic
surface covered with hydrocarbons (THCPSi) (Björkqvist et al. 2004; Salonen et al. 2004;
Salonen et al. 2008; Alvarez et al. 2009). A novel surface chemistry procedure, thermal
functionalization of THCPSi with undecylenic acid (UnTHCPSi) produces a moderately
hydrophilicsurfacewithhydroxylgroups,whichcanbeeasilyfurthermodified.Asfaraswe
areaware,thepharmacokineticparametersofpeptidesaftertheadministrationinPSiandthe
effects of different surface chemistries of PSi on those parameters have not been reported
earlier.
 Our recent in vivo studieswith several differentphysiological parameters indicated that
THCPSimicroparticles could sustain the in vivo effectsofpeptides (Kilpeläinenet al. 2009,
2011).Favorably,peptideloadingontoPSidoesnotrequirestressfulprocedures,whichcould
damage the molecules leading to their bioinactivation, which has been a problem with
various particulate systems (Witschi andDoelker 1998; Frokjaer andOtzen 2005; Ye et al.
2010).
 In attempts to investigate its physiological functions, PYY336 has been delivered
chronicallyviaosmoticminipumpsor infusionsusingdifferentexperimentalarrangements
in laboratory animals (Chandarana and Batterham 2008; Karra and Batterham 2010).
However, because of thepromising characteristics ofPYY in the treatment of obesity, also
othersuitabledeliverysystemshavebeeninvestigated,aspresentedinSection2.2.Sinceall
ofthesetesteddeliverysystemswouldrequirefrequentrepeatedadministration,asustained
release systemwouldbepreferable. Furthermore, a sustained release systemcouldhelp to
overcomethesideeffectsevokedbyhighdosesaswellaseliminatingtheneedforfrequent





6.2 MATERIALS AND METHODS 
6.2.1Reagents
The silicon wafers were purchased from Cemat Silicon S.A. (Warsaw, Poland). Ethanol




Human PYY336 (PYY336,Mw 4050 g/mol)was prepared by BCN Peptides (Barcelona,
Spain).HPLCreagentswereacetonitrile(HPLCgrade,JTBaker,Deventer,TheNetherlands),
trifluoroaceticacid(Sigma–Aldrich,St.Louis,MO,USA).pH7.4,0.15Mphosphatebuffered
saline (PBS, =0.167)was used as a buffer in the in vitro release experiments. The buffer
contained 8.0 g sodium chloride (JT Baker Deventer, The Netherlands), 0.2 g potassium
chloride (MerckKGaA,Darmstadt,Germany), 1.4gdisodiumhydrogenphosphate (Merck
KGaA, Darmstadt, Germany) and 0.2 g potassium dihydrogen phosphate (Merck KGaA,










Aiming to remove any remaining small particles, after the dry sieving the particles were
washedona38msievewithethanol.Themicroparticlesweretreatedwitha1:1HF:EtOH
solution to replace the oxidized surface formed during the milling with a hydrogen
terminationanddriedat65°Cfor1h.
Thermal hydrocarbonization of PSi microparticles (THCPSi) was performed under
continuousN2/acetylene (1:1) flow as described earlier (Salonen et al. 2004). Treatment at
500°Cfor10minwasusedinordertomaintainpartialhydrocarbonterminatedandhencea
hydrophobicsurface.
Functionalization of THCPSi microparticles was made by thermal treatment of the
particles inundecylenic acid (UnTHCPSi) at 120°C for 16h adapting the treatment for the
hydrogen terminatedPSi introducedbyBoukherroubet al. (2002).Due to the stressedand
unsaturated carboncarbon bonds existing on the hydrophobic surface ofTHCPSi particles
immediatelyafter thethermalhydrocarbonization,undecylenicacidcovalentlybindstothe
THCPSi surface and a treatment efficiency of about 50% can be achieved compared to the
hydrogen terminatedPSi (Fig. 6.1). This clearly changes the characteristics of theparticles,
such as their drug loading and release properties, hydrophilicity and zeta potential. In
addition, the carboxyl groups attached onto the surface can be used for further
functionalization of the particles. Thermal oxidation of PSi microparticles (TOPSi) was




Figure 6.1. TG measurements of thermally oxidized PSi (TOPSi), hydrocarbonized PSi (THCPSi) 
and undecylenic acid treated thermally hydrocarbonized PSi (UnTHCPSi) and PYY3-36 loaded 













according to BJHtheory (Barrett et al. 1951). The calculated values for TOPSi revealed an
averageporediameterof10.3nm,specificsurfaceareaof222m2/gandporevolumeof0.76
cm3/g, forTHCPSi;averageporediameterof11.2nm,specificsurfaceareaof273m2/gand
pore volume of 0.94 cm3/g and forUnTHCPSi; average pore diameter of 10.4 nm, specific
surface area of 231m2/g andpore volume of 0.76 cm3/g,which slightly reduce during the
surfacetreatments(Table6.1).
Table 6.1. The characteristics of PSi microparticles (38–53 μm) and PYY3-36 release behavior in
vitro and in vivo. 
6.2.3Particleloading
PYY336 (pI 7.6)was dissolved inwater and the PSimicroparticleswere immersed in the
peptide solution (100mg/ml,pHca7) for1.5hat room temperature.The loadingsolution































at 1 h (ng/ml) 
TOPSi 10.3 222 14.4–15.2 0.16 0.76 27±2.7 102.7±10 
THCPSi 11.2 273 12.2 0.11 0.94 14.5±3 6.1±0.8 




Figure 6.3. ATR-FTIR spectra of solid peptide PYY3-36 compared with PYY3-36 loaded THCPSi, 
UnTHCPSi and TOPSi. 
6.2.4Invitrorelease
Approximately 2 mg of PYY336 loaded TOPSi, THCPSi or UnTHCPSi microparticles
(containing 293, 250 and 347 g PYY336 in TOPSi, THCPSi andUnTHCPSi, respectively)
weresuspended in1.5mlofprewarmed0.15MPBSbuffercontaining0.1%w/vBSA(pH
7.4,=0.167,+37°C)inmicrocentrifugetubes.Thesetubeswereplacedinawaterbathshaker
(GrantOLS200,Cambridge,UK)with orbital shaking at a frequency of 120 strokes/min at
+37°C.Atpredeterminedtimeintervals,thetubeswerecentrifugedfor2min(13000rpm,17
000g,HerauesBiofugeFresco,Osterode,Germany),andsupernatantswerecollectedforthe
HPLC analysis of PYY336 concentrations. The microparticles were resuspended in fresh
prewarmed(+37°C)PBSbuffercontainingBSA(0.1%w/v)after thesupernatantcollection.
The concentration ofwater solublePYY336 in bufferwas <10%of itsmaximum solubility
(~100 mg/ml in water), and therefore sink conditions were maintained throughout the
experiment.
6.2.5HighperformanceliquidchromatographyanalysisofPYY336
The samples from PYY336 in vitro release experimentwere analyzedwith a GilsonHigh
PerformanceLiquidChromatograph.ThesystemconsistedofanUVdetector(UV/VIS151),
pump (321), autoinjector (234), interface (506 C) and integrator (Unipoint 3.0). Themobile
phasewas amixture of acetonitrile (31.5% v/v),water (68.5% v/v) and trifluoroacetic acid





were determined by measuring peak areas, which were compared to a linear calibration
curvepreparedusingknownstandardPYY336concentrations(1–50g/ml).
6.2.6Invivoexperiment
TheBALB/cxDBA2hybridmice, for investigatingPYY336plasmaconcentrationsafter its
intravenousandsubcutaneousdeliveryindifferentformulations,werepurchasedfromLab






Inc.) and tap water were available ad libitum throughout the experiment. The research
adhered to the Principles of Laboratory Animal Care. The National Animal Experiment
BoardofFinlandapprovedtheexperiments.Procedureswereconductedinaccordancewith




and5)20gofhumanPYY336was injected in0.9%NaClsolution intravenously through
lateraltailveininavolumeof100l.Bloodsampleswerecollectedfromsaphenousveinat
predetermined time points into heparinized microcapillaries (Drummond Microcaps,
DrummondScientificCo.Broomall,Pa.USA).Plasmawasseparatedbycentrifugation(+4°C,
3 min, 12000 rpm, Heraues Biofuge Fresco, Osterode Germany) and frozen immediately.


























respectively. Sustained PYY336 deliverywas achievedwith all themicroparticles, TOPSi,
THCPSiandUnTHCPSibutthesurfacechemistrystronglyaffectedthePYY336releaseboth








PYY336 release fromTOPSi, THCPSi andUnTHCPSimicroparticleswasmeasured for 14
days in vitro (Fig. 6.4). There was sustained but incomplete PYY336 release from all the
investigatedsurfacesandthesurfacechemistryaffectedthefractionofpeptidereleased.The
highest peptide fraction was released from TOPSi (27.7±2.7% of loaded PYY336,
mean±SEM) followed by THCPSi (14.5±3.0%) and UnTHCPSi (6.2±0.6%) microparticles,
indicatingweaker in vitro interactions betweenPYY336 andTOPSi thanbetweenPYY336
and THCPSi or UnTHCPSi. This hypothesis is supported by anATRFTIR analysis of the
peptide loaded PSi. The spectral features of PYY336 are superposed on the characteristic
spectraofthedifferentPSisurfacechemistriesafterthepeptideloading,aspresentedinFig.
6.3.ThemostnotablefeaturesareappearanceofthebroadamideIandIIbandscenteredat
1650 cm1 and 1550 cm1. Compared with the solid PYY336, used as a reference, the
adsorptionintoPSidoesnotcausemajoralterationstotheFTIRspectraofthepeptide.The
PYY336 loadedTOPSi showspractically nodetectable changes in the characteristic amide
bandregions,forexample,theamideIbandat1650cm1doesnotindicateappreciableshift




inaparticularconformation (ArrondoandGoni1999).As themaindifferencebetween the
PSi surface chemistries is their hydrophilicity, the shift in the amide bands presumably
indicatesthatpeptidehasaslightlydifferentorientationaftertheadsorptiontotheporewall
surfaceofTHCPSiorUnTHCPSimicroparticles.
Figure 6.4. In vitro PYY3-36 release from PSi microparticles with three different surface 
chemistries (PBS, pH 7.4, +37°C) (Mean ± SEM, n = 4). 
6.3.2PharmacokineticsofPYY336aftersubcutaneousdeliveryviaPSimicroparticlesin
mice














THCPSi, respectively, whereas the halflife of the PYY336 solution was a mere ~25 min
(Table6.2).ThisisevidenceforsocalledflipfloppharmacokineticsforPYY336deliveryvia
PSi microparticles since the peptide release from the microparticles controls the detected
PYY336plasmaconcentrations(Boxenbaum,1998).
Figure 6.5. Sustained PYY3-36 release after delivery in PSi microparticles is affected by surface 
chemistry of the microparticles (THCPSi and UnTHCPSi n = 6, TOPSi n = 5, PYY3-36 solution s.c. n
= 4, mean ± SEM). *TOPSi vs. THCPSi/UnTHCPSi p < 0.001 0–1 h; p < 0.005 TOPSi vs. 
THCPSi/UnTHCPSi at 4h. 

Table 6.2. Pharmacokinetic values of PYY3-36 (dose 20 μg) after subcutaneous (s.c.) and 
intravenous (i.v.) administration in mice. PYY3-36 was delivered in solutions (i.v., s.c.) and in 
mesoporous silicon (PSi) microparticles (s.c.) with different surface chemistries; thermally 
oxidized (TOPSi), thermally hydrocarbonized (THCPSi) and thermally functionalized THCPSi with 
undecylenic acid (UnTHCPSi). (Mean ± SEM, n = 4–6) 
  PYY sol i.v. PYY sol s.c. TOPSi s.c. THCPSi s.c. UnTHCPSi s.c. 
Cmax (ng/ml) 2327±725 137±35c 103±8a,b 22±6a,b,c 13±2 a,c 
tmax (min) 3±1 26±11 51±9d 11±2d 19±8d 
t½ (h) 0.4±0.02 0.4±0.02c,d 7±1a,d 20±1a,c 21±2a,c 
AUC0-last (h ng/ml)  471±75 181±31a 457±73a 59±5a 44±5a 
AUC0- (h ng/ml)  471±75 181±31a 462±73a 61±6a 45±5a 
F (%)  38 ±7a 98 ± 16a 13 ±2a 9± 1a 





hencemodified the pharmacokinetics (Table 6.2). The highest PYY336 peak concentration
(Cmax) was obtained for TOPSi being 103±8 ng/ml, when the corresponding values for
THCPSiandUnTHCPSiwere22±6ng/mland13±2ng/ml,respectively.However,thetime
when the Cmax was reached (tmax) with TOPSi (51±9min)was significantly delayedwhen
compared with tmax values of THCPSi and UnTHCPSi (11±2 min and 19±8 min,




concentrations were significantly higher until 4 h after the administration with TOPSi
microparticlescomparedwithTHCPSiandUnTHCPSi.
Thirdly, the extent of released fraction of PYY336 exhibited the same rank order
TOPSi>THCPSi>UnTHCPSi invitro and invivo,but theabsorbed fractionswerehigher in
vivo than the released fractions in vitro (Figs. 6.4 and 6.5). The absolute bioavailability of
PYY336afteradministrationinTOPSiwas98±16%indicatingcompletepeptidereleaseand
absorption from theparticles,while the absolutebioavailabilities afterPYY336delivery in
THCPSi and UnTHCPSi were 13±2 and 9±1%, respectively (Table 6.2). Interestingly, the
bioavailabilityofs.c.PYY336solutionwasonly38±7%.Therelativebioavailabilities,when
compared with s.c. solution, of PYY336 after administrations in TOPSi, THCPSi and
UnTHCPSiwere256±41%,34±3%and25±2%,respectively(Table6.2).
6.4 DISCUSSION 
The experimental protocol and the results are summarized in Fig. 6.6. The ATRFTIR
analysis of the loaded TOPSi, THCPSi and UnTHCPSi do not indicate strong interactions
betweenthePSisurfaceandtheloadedPYY336.Instead,thenegligibledifferencesobserved
with TOPSi may indicate that combined with the better wettability of the material, the
peptide is readily desorbed from the surface, while with more hydrophobic THCPSi and
UnTHCPSi PYY336 may be oriented towards the surface of the PSi according to its
hydrophobic segments. The carboxylic acid terminated UnTHCPSi surface additionally
indicatesslightlystrongerconformationalchangesthanTHCPSi,asthehelixstructureand
random conformation related peaks at 1654 cm1 and 1641 cm1 becomemore pronounced
(Hegefeld et al. 2011). The presence of possible hydrogen bonding between the surface
carboxylgroupsandthepeptideaminegroupscannotbeexcluded,asboththeamideIband
andtheadjacentcarbonylpeakat1715cm1overlapconsiderably.
SurfacechemistryofPSi clearlyaffected invitro (Fig.6.4)and invivo releaseofPYY336
(Table 6.2). Both in vitro and in vivo results indicate that TOPSi released PYY336 most
efficientlybuttheabsorbedfractionofPYY336washigherinvivothanthereleasedfraction
in vitro. These results demonstrate the importance of both surface chemistry and release
medium in the release of PYY336 from PSi. The interactions between PYY336 and PSi




their dissolution (Park et al. 2009). Of the PSi microparticles investigated here, the
degradation rate of TOPSi is the fastestwhileTHCPSi is themost stabile.To illustrate the
complexity between the PSi in vitro and in vivo results, it was recently shown that PSi
degrades faster in serum, than in phosphate buffered saline (PBS) (Godin et al. 2010),
supportingourobservationsof significantly faster invivodegradationofTHCPSi (Fig.4.3).
Therefore,thePSidegradationmightnotaffectsignificantlythepeptidereleaseinvitrointhe








Figure 6.6. PYY3-36 was loaded into the nanopores of porous silicon microparticles with three 
different surface chemistries. The formulations were investigated both in vitro and in vivo. The 
surface characteristics clearly influence the PYY3-36 delivery. TOPSi improves the relative 
bioavailability and UnTHCPSi shows the most sustained release. 
 
Recently, interactions of three proteins, HSA, lysozyme and papain with TOPSi
microparticleswere investigated in vitro and TOPSiwas shown to be able to preserve the
native structure of the proteins and therefore the investigated proteinswere suggested to
maintaintheirbiologicalactivity(Jarvisetal.2010).Inaddition,arecentstudyregardingthe
adsorption of lysozyme on silica nanoparticles indicated that even the conformation of a
peptidemay change due to the adsorption, these changes are reversed during desorption
(Felsovalyi et al. 2011).Themethodused in thepresent study, fordetectingPYY336 from
plasma(ELISA), isbasedonspecificantibodybindingtoactivehumanPYY.Therefore, the
assay confirms theactivityof thedeliveredpeptide. In thepresent study,PYY336 loading
into PSi microparticles protected PYY336 from degradation before its release from the
particles,sincethepeptidecouldbedetectedduringseveraldaysfromthebloodcirculation.
The interesting result is that the TOPSimicroparticles significantly improved the absolute
bioavailabilityofPYY336 (98±16%) from thatof the s.c. solution (38±7.5%).These results
suggest that a complete absorptionof subcutaneousPYY336 requires a tailored controlled
release formulation instead of an immediate release formulation, such as solution. Also a
permeationenhancingfeatureofPSicouldalsoaccountforimprovedbioavailabilitysincePSi
hasbeenreported to improve the invitropermeationof furosemide (Kaukonenetal.2007)
andinsulinthroughCaco2monolayers(Forakeretal.2003).However,itmustbenotedthat,
despitethepromisingearlierandpresentresults,TOPSimightnotbeoptimalforallpeptides






This work demonstrates that PSi microparticles are capable to achieve a high a peptide
loading degree and sustained in vivo PYY336 delivery over several days. In addition, the
peptidereleasingpropertiescanbemodifiedwithdifferentsurfacechemistriesandtherefore




























on cytokine release have been investigated, but the properties of hydrophobic, thermally
hydrocarbonized PSi nanocarriers have not been evaluated (Kim et al. 2009; Tanaka et al.
2010a). Therefore, the presence of various cytokines was investigated here after single
intravenous(i.v.)deliveryof thermallyhydrocarbonizedPSinanocarriers inmice.Thedata
presentedhereisunpublished.
7.2 MATERIALS AND METHODS 
7.2.1Materials
The siliconwafers, forproductionof thePSiparticles,werepurchased fromCematSilicon
S.A.(Warsaw,Poland).Ethanol(99.5%)wasfromAltia(Helsinki,Finland).Hydrofluoricacid
(HF) (37% – 39%)was purchased fromMerckKGaA (Darmstadt, Germany). The nitrogen






food pellets (Teklad 2016, Harlan Inc.) and tap water were available ad libitum. The
NationalAnimalExperimentBoardofFinlandapproved theexperiments.Procedureswere




Constant current densities of 50 and 200 mA/cm2 were used one ofter another to obtain
multilayered PSifilm. Milling of the PSi films into nanoparticles (average 109.1 nm, PDI
0.117, Zetasizer Nano ZS, Malvern) was performed in isopropanol. Thermal
hydrocarbonization (THCPSi) of the particleswas performed in acetylenenitrogen flow at
500°C.TheTHCPSiparticleswere resuspended into aqueousTweenusingultrasoundand
sizefractionedbycentrifugation.Subsequently,theparticleswerewashedwithethanoland






In order to investigate the effects of single i.v. administration THCPSi nanoparticles on
cytokine activity, 300 g of heat sterilized THCPSi nanoparticles were injected in 100 l
volume of 6.8% (w/v) HEPES through the lateral tail vein to mice (n=6). Control groups
receivedeither100l6.8%HEPES(i.v.,n=6)orLPS(2g/kgin6.8%HEPES,s.c.,n=6).The
positive control, LPS,was administered s.c. in order to avoid toomassive response to i.v.
deliveredLPS.Blood sampleswere collected fromsaphenousvein1, 3, 6, 24and48hours
after the injections. Plasma was separated by centrifugation (+ 4 °C, 3 min, 12500 rpm,
HerauesBiofugeFresco,Osterode,Germany), frozenandstoredat–70 °Cuntil the sample
analysis. The cytokine concentrationswere latermeasured using BioPlexMouseCytokine
Panel with BioPlex instrument and following the manufacturer	s instructions (BioPlex®,
BioRadLaboratoriesInc.).
7.3 RESULTS AND DISCUSSION 
Thei.v.deliveryofdrugfreeTHCPSinanoparticlesdidnotinduceanymajorinflammatory
reactionsduring48hoursaftertheadministrationasthecytokinelevelsweresimilartothose
of the controlmice (Fig. 7.1). In contrast, the positive control (LPS) increasedmost of the
measured markers significantly, as expected. The detailed plasma concentrations are
presentedinTable7.1.
 Previously,oxidizedporoussiliconandAPTEStreatedporoussiliconparticles(sizeofca
1.5 m, 107–5x108 particles, ca 0.5mg)were injected i.v. and nomajor effects on cytokine
levels could be detected after single or weekly administration during a 4week period
(Tanaka et al. 2010a).However, different particle surfacesmight inducedifferent reactions
(Ainslie et al. 2008). Here, results for hydrophobic THCPSi nanocarriers, after single i.v.

























Figure 7.1. Plasma cytokine concentrations at A) 1, B) 3, C) 6, D) 24 and 48 hours after 







Table 7.1. Plasma cytokine levels after i.v. delivery of THCPSi nanocarriers in mice.
CYTOKINE Time (hours) Treatment/concentration in plasma 
(pg/ml, mean ± SEM) 
  HEPES LPS THCPSI 
Il-1 1 65±3 74±5¤ 55±4 
 3 48±1 55±4 41±2 
 6 48±4   59±3 
 24 57±7 53±3 41±2 
 48 39±2 63±4**,¤¤ 38±2 
     
Il-1 1 11±2 44±5 9±2 
 3 11±2 197±9****,¤¤¤¤ 14±2 
 6 11±3 144±34****,¤¤¤¤ 13±3 
 24 38±9 144±4****,¤¤¤¤ 22±9 
 48 12±2 45±6 9±4 
     
IL-2 1 6±0.3 11±0.8 5±0.5 
 3 5±0.3 35±1****,¤¤¤¤ 5±0.4 
 6 5±0.4 27±6****,¤¤¤¤ 5±0.2 
 24 5±1 31±2****,¤¤¤¤ 5±1 
 48 4±0.5 18±1****,¤¤¤¤ 4±0.3 
     
IL-3 1 3±1 5±0.7 1±1 
 3 2±1 17±1 1±0.6 
 6 2±0.5 10±2.5 1±0.4 
 24 2±1 11±0.5 1±0.6 
 48 2±1 11±1 2±1 
     
IL-5 1 2±0.3 4±1 2± 
 3 13±2 15±3 15± 
 6 18±4 19±3 20± 
 24 3±0.3 7±0.5 3± 
 48 1±0.2 3±0.5 1± 
     
IL-6 1 17±3 2670±586****,¤¤¤¤ 16±2 
 3 32±7 5794±661****,¤¤¤¤ 68±20 
 6 176±72 1487±465* 365±134 
 24 141±42 286±29 181±144 
 48 35±11 181±74 48±22 
     
IL-9 1 13±0.5 38±2 8±2 
 3 9±1 231±9****,¤¤¤¤ 8±1 
 6 9±1 186±45****,¤¤¤¤ 10±2 
 24 9±2 184±13****,¤¤¤¤ 10±4 
 48 7±1 41±4 8±1 
     
IL-10 1 13±3 282±70****,¤¤¤¤ 19±7 
 3 20±4 128±11**,¤¤ 21±3 
 6 18±3 125±31**,¤¤ 18±3 
 24 13±4 184±15****,¤¤¤¤ 12±3 
 48 11±2 71±4 11±2 




Table 7.1. Plasma cytokine levels after i.v. delivery of THCPSi nanocarriers in mice.  
(Table continues from the page 60) 
CYTOKINE Time (hours) Treatment/concentration in plasma 
(pg/ml, mean ± SEM) 
  HEPES LPS THCPSI 
IL-12 (P40) 1 49±9 67±8 56±3 
 3 46±7 1011±191****,¤¤¤¤ 59±3 
 6 39± 
9
560±189****,¤¤¤¤ 56±2 
 24 33±5 131±10 40±1 
 48 38±6 48±2 43±2 
     
IL-12 (P70) 1 12±2 20±1 9±1 
 3 10±2 54±3****,¤¤¤¤ 10±1 
 6 9±1 36±8****,¤¤¤¤ 10±1 
 24 10±3 45±4****,¤¤¤¤ 12±3 
 48 8±2 36±3****,¤¤¤¤ 9±1 
     
IL-13 1 44±3 92±7 33±3 
 3 28±4 448±25****,¤¤¤¤ 23±1 
 6 30±3 293±70****,¤¤¤¤ 24±2 
 24 40±15 367±46****,¤¤¤¤ 39±11 
 48 15±4 165±16***,¤¤¤ 28±7 
     
IL-17 1 6±1 8±0.7 4±0.4 
 3 5±1 26±0.6****,¤¤¤¤ 5±0.6 
 6 5±0.9 18±4***,¤¤¤ 4±0.2 
 24 9±5 23±2***,¤¤¤ 6±2 
 48 4±0.7 14±1**,¤¤ 4±0.3 
     
EOTAXIN 1 529±61 823±57 418±72 
 3 663±47 2379±170****,¤¤¤¤ 343±89 
 6 700±101 2435±692****,¤¤¤¤ 509±109 
 24 482±43 3997±362****,¤¤¤¤ 303±33 
 48 479±39 1002±142 297±58 
     
G-CSF 1 52±4 584±171 58±5 
 3 67±10 90428±16691****,¤¤¤¤ 79±8 
 6 90±12 90596±31666****,¤¤¤¤ 133±26 
 24 55±9 72051±15310****,¤¤¤¤ 57±21 
 48 37±6 1185±195 39±7 
     
GM-CSF 1 19±0.5 40±2 13±4 
 3 15±1 110±2****  13±2 
 6 13±1 81±17****  14±2 
 24 14±3 118±8****  9±3 
 48 8±0.8 63±6****  8±3 
   (Table continues on the page 62) 
     
     
     




Table 7.1. Plasma cytokine levels after i.v. delivery of THCPSi nanocarriers in mice.  
(Table continues from the page 61) 
CYTOKINE Time (hours) Treatment/concentration in plasma 
(pg/ml, mean ± SEM) 
  HEPES LPS THCPSI 
IFN- 1 11±0.6 17±0.7 7±2 
 3 8±0.9 58±3**** 7±1 
 6 9±0.7 39±9**** 7±0.5 
 24 11±4 51±3**** 10±3 
 48 5±0.7 30±2**** 5±0.7 
     
KC 1 14±0.7 623±152 23±3 
 3 20±2 6226±1548****,¤¤¤¤ 29±4 
 6 27±6 1164±453 27±3 
 24 28±5 146±7 25±10 
 48 12±0.8 38±12 13±3 
     
MCP-1 1 36±2 830±281 61±9 
 3 37±5 26347±0 163±21 
 6 48±10 4292±2109****,¤¤¤¤ 95±10 
 24 65±19 1578±359 75±24 
 48 28±3 271±74 30±4 
     
MIP1-  1 86±12 199±20¤ 54±6 
 3 71±13 514±12****,¤¤¤¤ 44±11 
 6 75±13 389±75****,¤¤¤¤ 56±7 
 24 97±24 382±8****,¤¤¤¤ 47±8 
 48 83±31 197±14 37±9 
     
MIP1- 1 26±6 623±125***,¤¤¤ 33±6 
 3 24±7 2097±227****,¤¤¤¤ 30±1 
 6 23±7 864±219****,¤¤¤¤ 29±2 
 24 64±15 460±36*,¤ 43±15 
 48 21±3 136±39 20±4 
     
RANTES 1 71±7 103±8 61±9 
 3 66±8 1589±229****,¤¤¤¤ 71±12 
 6 58±8 2017±538****,¤¤¤¤ 65±10 
 24 63±7 866±68**,¤¤ 88±15 
 48 72±9 262±22 76±9 
     
TNF- 1 65±16 3578±312****,¤¤¤¤ 39±3 
 3 56±15 472±51*,¤¤ 39±4 
 6 53±16 216±52 39±2 
 24 74±22 186±9 48±9 








Porous silicon (PSi) is receiving growing attention in biomedical research, for example in
drugandpeptidedelivery.InspiredbyseveraladvantagesofPSi,herein,thermallyoxidized
(TOPSi, hydrophilic), undecylenic acid treated thermally hydrocarbonized (UnTHCPSi,






the s.c. PSi nanocarriers despite of surface chemistry. In contrast, i.v. delivered PSi






















Nanocarriers canbeutilized for enteral andparenteral routesand theymay improvedrug
delivery by increasing drug solubility and bioavailability, controlling and targeting drug








 It has been demonstrated that PSi is suitable for both enteral and parenteral drug
administration; for example, incorporation into oxidized PSi microparticles improved




thekidneysor to accumulate into liver after intravenous (i.v.)delivery inmice (Park et al.
2009).Drugfree18FlabeledthermallyhydrocarbonizedPSinanoparticleswerealsoshownto







that theparticle loadingcanbeperformedat roomtemperaturewithoutstrongsolventsor
severalstressfulphasesduringfabrication,whichisoneadvantageofusingPSi(Kilpeläinen
etal.2009).
 Recently,wehavedemonstratedthat invivoPYY336release iscomplete fromthermally





for drug release from the pores of the particles. Thermally oxidized PSi has a hydrophilic
surface,whereas in contrast, the surfaceof thermallyhydrocarbonizedPSi is hydrophobic.
When undecylenic acid is linked covalently on the hydrocarboncovered thermally
hydrocarbonized PSi surface, the surface becomes moderately hydrophilic due to the
carboxyl groups. In the present study, the effects of PYY336 loading into three different
typesofPSinanocarrierswereevaluatedonitspharmacokineticparametersafters.c.andi.v.
delivery.
8.2 EXPERIMENTAL SECTION 
8.2.1Reagents
The silicon wafers, for production of the PSi nanocarriers, were purchased from Cemat
Silicon S.A. (Warsaw, Poland). Ethanol (99.5%)was bought fromAltia (Helsinki, Finland).
Hydrofluoricacid(HF)(37%–39%)waspurchasedfromMerckKGaA(Darmstadt,Germany).




Finland). Sodium chloride solution (9 mg/ml) for injections was obtained from B. Braun
MelsungenAG(Melsungen,Germany)andHEPESwasfromSigma–Aldrich(St.Louis,MO,
USA). Human PYY336 (PYY336, Mw 4050 g/mol) was purchased from BCN Peptides
(Barcelona, Spain). Highperformance liquid chromatography (HPLC) reagents were




Constant current densities of 50 and 200 mA/cm2 were used consecutively to obtain
multilayered PSifilm. A cyclic etching current leads to the formation of a brittle fracture
layer,betweenthemesoporouslayers,whichenhancesthenanoparticleyieldinmilling.
 Thermal oxidation of PSi (TOPSi) was conducted in air at 300 °C for 2 h. Thermal
hydrocarbonization was made in acetylenenitrogen flow at 500°C, which creates a
hydrophobic, hydrocarbon terminated surface (THCPSi). Further functionalization of
THCPSifilmswasmadeviacovalentattachmentof1undecylenicacidtothesurfacecarbons
byasimilarreactionasdescribedbyBoucherroub(Boukherroubetal.2002). Inthepresent




THCPSi in 1decene. The obtained polydisperse PSi suspension was subsequently
fractionated by exploiting the faster sedimentation of larger particles. TOPSi ethanol
suspensionwasallowedtosedimentforafewhours,andthesupernatantwascollectedfor
further fractioning. The THCPSi and UnTHCPSi suspension medium was changed to
ethanolicmediums(5%w/wsuccinicacidinethanoland80%w/wethanol,respectively)by
centrifugationandsedimentation,asdescribedabove.Aftersedimentation, theparticlesize











(Zetasizer Nano ZS, Malvern). Measurements were repeated at least five times (10 mM
phosphatebuffer,pH7.5)andtheaverageswithstandarddeviationsarereported.
 The specific surface area, pore volume and pore size were characterized with nitrogen
sorptionmeasurements(TriStar3000,MicrometricsInc.)at–196°Cforthes.c.nanoparticles.
BET theoryand singleadsorptionpointmethodwereused to calculate the specific surface
areaandporevolume,respectively.Theaverageporediameteriscalculatedfromthesurface
area andporevolume (D= 4V/A) andgives an estimationof theporediameter, assuming







Table 8.1. Surface area, pore volume, average pore diameter, -potential and PSD of s.c. PSi 
nanocarriers. 















 (mean and 
width, nm) 
TOPSi hydrophilic 163 0.591 15.3 –47.8±2.7 163±66 
UnTHCPSi moderately 
hydrophilic 230 0.706 12.3 –40.5±1.6 180±66 
THCPSi hydrophobic 202 0.598 11.8 –31.4±3.5 157±67 
8.2.5PYY336adsorptionintoPSinanocarriersinvitro
Todeterminethe timerequiredforefficientpeptide loading in the invivo studies,PYY336
adsorption into TOPSi, THCPSi and UnTHCPSi nanoparticles was investigated in vitro in
experimentI(Table8.2).Theparticlesweresuspendedinwater,andaliquotsofPYY336and
HEPES (6.8% w/w) were added to achieve the volume of 400 l. The suspension was
incubatedfor60minatroomtemperatureandthePYY336concentrationofthesupernatant
wasdeterminedatpredefined timepointsup to60min. In in vitro experiment II, the final
loading efficacy of PYY336 into nanoparticles was examined after 60 min in conditions
resemblingthoseusedforinvivoadministration.Becauseofpracticalandanalyticalreasons,
in invitroexperimentII, thePYY336/PSiratiowas5and50timeshigherthanins.c.ori.v.




Table 8.2. Experimental conditions of the in vitro PYY3-36 adsorption experimentsa  




















analytical column was a reversephase Supelco Discovery Biowide® C18 column
(150×4.0mm id, particle size 5m, Supelco, Bellefonte, PA,USA)whichwas placed in a
columnheaterduring theanalysis (+40 °C).The injectionvolumewas100l, and the flow
rate1ml/minwithPYY336beingdetectedat200nm.
8.2.7Animals
TheNationalAnimal Experiment Board of Finland approved the experiments. Procedures




relative air humidity 55 ± 15% and 12/12 hour light/dark cycle with lights on at 7 am.






In the determination of plasma concentrations and pharmacokinetics of PYY336 after s.c
delivery via PSi nanocarriers, TOPSi, THCPSi and UnTHCPSi nanoparticles were loaded
withPYY336immediatelypriortotheiradministration.Intheloadingsuspension,theratio
ofPYY336toPSinanocarrierswas20g:1250ginwater,respectively.Duringtheloading,
the suspensionwas sonicatedoccasionally to ensure ahomogenous suspension.After a 60
minincubationoftheloadingsuspensionatroomtemperature,HEPESsolutionwasadded
toachievea6.8%(w/v)concentration.
 The different formulations containing 20 g of human PYY336with 1250 g either (1)






bycentrifugation (+4 °C,3min,12500 rpm,HerauesBiofugeFresco,Osterode,Germany),
frozeninstantlyandstoredat–70°CuntiltheanalysiswithtotalhumanPYYenzymelinked
immunosorbent assay (ELISA) following the manufacturer’s instructions (Millipore Corp.,
Billerica,MA).
8.2.9IntravenousdeliveryofPYY336loadednanocarriers
In the determination of the concentrations and pharmacokinetics of PYY336 after i.v.





TOPSi (n=6) (2) THCPSi (n=10) (3) UnTHCPSi (n=6) nanoparticles or in (4) 6.8% HEPES
solution(n=10)wereadministeredi.v.tomiceviathelateraltailveininavolumeof100l.
Bloodsampleswerecollectedat1,15,60,90and180minaftertheinjectionsfromsaphenous
vein into heparinized microcapillaries (Drummond Microcaps, Drummond Scientific Co.
Broomall, Pa. USA). Plasma was separated by centrifugation (+ 4 °C, 3 min, 12500 rpm,
Heraues Biofuge Fresco, Osterode, Germany), frozen instantly and stored at –70 °C until
analysisasdescribedintheprevioussection.
8.2.10Pharmacokineticanalysis
Pharmacokinetic parameters for PYY336 were calculated from plasma concentration–time
data by using WinNonlin software (WinNonlin Professional, 5.3, Pharsight Corp, United
States)with the noncompartmentalmodel for extravascular or bolus intravenous injection
with uniform weighing. Cmax and tmax values were obtained directly from the plasma
concentration –timedata.Values of the areaunder the concentration time curve (AUC0last)
were determined by the linear trapezoidal rule and AUC0
value as follows: AUC0last +
Clast/Ke, where Clast was the last measured plasma concentration and Ke was the terminal
eliminationconstant.AbsoluteandrelativebioavailabilitieswerecalculatedusingAUC0last
values, Fabsolute% = AUC(PSi formulation or PYY336solution) /AUCi.v.solution x 100%, Frelative%= AUCs.c. PSi
formulation/AUCs.c.solutionx100%.
8.2.11Statisticalanalyses
The pharmacokinetic parameters of PYY336 were analyzed using 1way Anova with
Bonferroni posttest (GraphPadPrism 5.04 forWindows, GraphPad Software Inc., La Jolla
CA).ThePYY336concentrationsasafunctionoftimewereanalyzedusingtwowayAnova













determine the time required for efficient peptide loading, the loading time for in vivo
experimentswasselectedtobe60minasthePYY336adsorptionintoTOPSi,UnTHCPSiand
THCPSi nanocarriers reached a plateau within this time (Fig. 8.1). In experiment I,
hydrophilic TOPSi reached fastest the adsorption plateau. The loading efficiency of TOPSi
did not increasemore than 4 percentage points after 2 min loading and it showed lower
loadingefficiencyafter60min(30.4±5.3%),ascomparedwithUnTHCPSiandTHCPSi.The
morehydrophobicUnTHCPSishowedarelativelyhighloadingefficiencyalreadyafter2min
(36.4 ± 6.4%) that further increased to 48.5 ± 5.4% during 60 min. Themost hydrophobic
nanocarrier, THCPSi, reached a comparable loading efficiency (47.1 ± 2.9%) to that of
UnTHCPSi but showed a slower adsorption at the start of the experiment, as thePYY336




 When the loading efficiency of PYY336 into the nanoparticles was investigated in
conditions resembling those used in in vivo administration (i.e. in vitro experiment II), the
loading efficiencies after 60 min were >99.5% for UnTHCPSi and THCPSi and >96% for
TOPSi. Itmustbenoted that in this invitro experiment, thePYY336:PSinanoparticle ratio
was5and50timeshigherthanins.c.ori.v.doses,respectively.Therefore,itwaspostulated








andTHCPSinanocarriers (s.c.)and incontrolsolutions tomice (s.c.and i.v.).Theresulting
pharmacokineticparametersarepresentedinTable8.3.
 The results show that all the PSi nanocarriers prolongedmarkedly the PYY336 plasma
concentrationsafters.c.deliveryascomparedwiththes.c.solution(Fig.8.2).Asexpected,the





tmax values of PYY336. Importantly, all the s.c. PSi nanocarriers increased the relative




absolute bioavailabilities of PYY336 were over 80% after s.c. delivery with the PSi
nanocarriers,reflectingtheefficientreleaseofactivePYY336(Table8.3).

Figure 8.1. PYY3-36 loading efficiency (mean ± SD, n=4) on TOPSi, UnTHCPSi, THCPSi 
nanocarriers as a function of time in experiment I.  
 
 ThePYY336plasmaconcentrationswereanalyzedasa functionof time.Onehourafter
the injections, PYY336delivery inTOPSi resulted in statistically significant higherplasma
concentrations (13.7 ± 2.4 ng/ml) as an evidence of a larger burst release from TOPSi











Figure 8.2. PYY3-36 plasma concentrations up to 12 h (A) and 4 days (B) after s.c. delivery (20 
μg) in PSi nanocarriers (n=5–6) or solution (n=4) in mice (mean ± SEM). TOPSi nanocarriers 
showed larger PYY3-36 burst release as compared with UnTHCPSi and THCPSi, as indicated by the 
significantly higher plasma values at 1 h after the injections. (TOPSi vs. UnTHCPSi p<0.05; TOPSi 
vs. THCPSi p<0.001). The PYY3-36 plasma concentrations stayed elevated throughout the 




Table 8.3. Pharmacokinetic parameters of PYY3-36 (20 μg) after administration administration in 
PYY3-36 loaded PSi nanocarriers (s.c.) and solution (s.c. and i.v.) (Mean ± SEM, n=4–6). 
TOPSi UnTHCPSi THCPSi PYY3-36 sol s.c. PYY3-36 sol i.v. 
Cmax (ng/ml) 14.9±5.5a 11.8±2.9b 11.2±2.3c 136.8±34.5  2326.7±725.2a.b, 
tmax (h) 5.3±3.4 34.8±14.8 22.7±9.3 0.437±0.19 0.050±0.02 
t½ (h) 21.0±1.4d,e 27.7±4.3f,g 21.0±2.2h,i 0.427±0.02e,g,i 0.363±0.02d,f,h 
AUC0-last (h ng/ml)  380.4±62.5 486.8±105.8 395.5±49.4 180.5±31.2  471.0±74.8 
AUC0- (h ng/ml)  399.8±66.0 625.6±149.6 431.8±58.6 180.5±31.2 471.0±74.8 
Fi.v (%)absolute 80.8 ±14.5 103.4±24.6 84.0±11.5 38.3 ±6.6  100 
Fs.c.(%)relative 210.7 ±37.9 269.7±64.2 219.1 ±30.0 100   








To investigate i.v. peptide delivery using PSi nanocarriers, 0.2 g of PYY336 was
administered i.v. in TOPSi, UnTHCPSi and THCPSi nanocarriers, having average particle
sizesof181,139and165nm,withcomparableporousproperties,andinsolutiontomice.The
pharmacokineticparametersarepresentedinTable8.4.
 None of the i.v. PSi nanocarriers could significantly sustain the release of PYY336




UnTHCPSi resulted in significantly higher absolute bioavailability than its delivery in
THCPSi (126.8±22.3, 110.7±23, 49.7±4.6%, respectively) indicating incomplete releaseof
PYY336 from THCPSi nanocarriers. TOPSi and UnTHCPSi nanocarriers also achieved a
statistically significantprolongationof the terminalhalflife ofPYY336 comparedwith the
i.v. solution (25.8 ± 2.6, 45.7 ± 7.5 and 12.0 ± 1.0 min, respectively). When analyzed as a
functionoftime,thePYY336plasmaconcentrationat1minafterinjectionwassignificantly
higherafterdeliveryinTOPSi(13.5±7.5ng/ml)thaninUnTHCPSi(5.6±3.5ng/ml),THCPSi
(2.8 ± 2.1 ng/ml ) and solution (7.7 ± 1.0 ng/ml), as shown in Fig.8.3. In summary, the i.v.




Table 8.4. Pharmacokinetic parameters after i.v. delivery of PYY3-36 (0.2 μg) in PSi nanocarriers 
and solution. (Mean ± SEM, n= 6-10) 
  TOPSi UnTHCPSi THCPSi PYY3-36 sol. 
Cmax (ng/ml) 13.5±3.1a,b 5.6±1.3a 3.0±0.6b 8.1±1.0 
tmax (min) 1.00  3.3±2.3 5.2±2.1 3.8±1.9 
t½ (min) 25.8±2.6c,d, 45.7±7.5d,e,f 19.9±2.1f 12.0±1.0c,e 
AUC0-last (h ng/ml)  3.7±0.7 3.3±0.7 1.5±0.1 2.9±0.8 
AUC0- (h ng/ml)  3.8±0.7 3.3±0.7 1.5±0.1 3.0±0.8 
F (%)absolute 126.8±22.3g 110.7±23.0h 49.7±4.6g,h  100 
aTOPSiv.s.UnTHCPSip<0.05; bTOPSiv.s.THCPSip<0.001; cTOPSiv.s. solution; dTOPSiv.s.UnTHCPSip<0.001;





Figure 8.3. PYY3-36 plasma concentrations after i.v. delivery in THCPSi, TOPSi and UnTHCPSi 
nanocarriers and after i.v. solution in mice. (Mean ± SEM, n=6–10) (TOPSi v.s. UnTHCPSi and 
THCPSi p<0.0001; TOPSi vs. solution p<0.05 at 1 minute after the injections) 
8.4 DISCUSSION 
In the present study, PSi nanocarriers were examined for the first time in vivo for use in
parenteral peptide delivery. The observed differences in PYY336 delivery between the
surface chemistries of nanocarriers seem to be attributable to their different surface
characteristics, such as hydrophilicity, because the differences cannot be explained by the
variation of their porous properties (Table 8.1). Generally, the results indicate that the
investigated PSi nanocarriers are compatible with the peptide and do not compromise its
biologicalactivity,asthemethodusedherefordeterminingPYY336plasmaconcentrations
isaspecificELISAdetectingactivePYYmolecules.
 When administered s.c. or i.v., the nanocarriers encounter very different environments.
Bothi.v.ands.c.dataindicatelargerburstreleaseofPYY336fromTOPSinanocarriersthan
fromUnTHCPSiandTHCPSi(Tables8.3–8.4,Figs.8.2–8.3)thatcanbeexplainedbyweaker
interactions between PYY336 and TOPSi surface than with UnTHCPSi or THCPSi
(Kovalainenetal.2012).Whendelivereds.c.,PYY336wasreleasedvirtuallycompletelyfrom
all the PSi nanocarriers during the experiment (4 days), as the absolute bioavailabilities of
PYY36werealmost100% (Table8.3).After i.v.delivery,PYY336was releasedcompletely
from TOPSi andUnTHCPSi nanocarriers, whereas the absolute bioavailability of PYY336
wasonly49.7%afterdeliveryinTHCPSinanocarriers(Table8.4).
 Previously, drugfree 18Flabeled i.v. THCPSi nanoparticles were shown to accumulate
within 30min into liver and spleen in rats (Bimbo et al. 2010). The rapid clearancemight
explain the incomplete release of PYY336 from i.v. THCPSi nanocarriers. The high
bioavailabilities from i.v. TOPSi andUnTHCPSi nanocarriersmight result fromvery rapid
peptide releasewhen themorehydrophilicnanocarriersareexposed to thecirculationand
their better wettability improves the peptide release compared with the hydrophobic
THCPSi. Furthermore, hydrophilicity of the carrier is known to increase circulation time
(Alexis et al. 2008; Decuzzi et al. 2010). In addition, even though the drug carriers may
becomeaccumulatedinliverorspleen,theymaystillbeabletoreleasethepayload,aswas






nanocarriers, suggests that in addition to diffusion and peptidecarrier interactions,
competitiveadsorptionplaysarole in thepeptiderelease.Also, thedifferentenvironments
afters.c.andi.v.deliveryofnanoparticles,eitherstayingattheinjectionsiteordistributing
rapidlyviacirculation,respectively,mayaffectthepeptidereleasesincethereleasemediums
varyfromtheircontentsadsorbingonPSi.Previously,peptide invitro release fromPSihas
been shown to be incomplete in vitro PBS, but the in vivo results have suggested bigger
fractiontobereleased(Kilpeläinenetal.2011;Kovalainenetal.2012).However,despitean
attempt to simulate better the in vivo situation, in vitro release of a polypeptide (IGF1)
reachedonly60% fromPSinanoparticles,when the releasewas investigated in 1:2diluted
mouseplasma (Huhtala et al. 2012). In addition, the in vivo releasemaybe assistedby the






thenanocarriers forPYY336molecules, that is, thePSinanoparticlemasswasbigger (1250











PSinanocarrierdecreasedthe invivo releaserateofPYY336 indicatingthatpeptiderelease

























and poor oral bioavailability. Even though several techniques have been developed in
attemptstoimprovepeptidedelivery;themajorityofclinicalpeptidesarestilladministered
parenterallyoftenasfrequentinjections(Antosovaetal.2009).Currently,theincreaseinthe






favorableproperties as adrug carriermaterial. Itwas encouraging, thatPSiprolonged the
duration of action and sustained the release of s.c. delivered appetite regulating peptides.
Importantly, no signs of inflammatory reactions were observed after single s.c. and i.v.
administrationofPSimicroandnanoparticles,respectivelyinmice.PSimarkedlyimproved
pharmacokineticparametersofs.c.administeredPYY336andperhapsmoreimportantly,the
release characteristics couldbe tailoredby changing thePSi surface chemistry andparticle
size. Furthermore, PSi nanocarriers were shown to be suitable also for i.v. peptide
administration,buttoachievesustainedi.v.peptidedeliverythePSinanoformulationsneed
tobefurtherdeveloped.
 First, GhA (Mw 930 g/mol) andMTII (Mw 1024 g/mol) were incorporated into THCPSi
microparticles.Advantageously, the fabricationof thePSidelivery system canbe achieved
without using strong solvents or a high temperature, i.e. avoiding conditions that may
jeopardizepeptide’sbiologicalactivity.Assuringthebiologicalactivityoftheformulationis
crucial,sincetheeffectofthepossibleconformationalchangesonthebioactivity,duringthe
manufacturing, is dependentwhether the change is permanent or reversible (Frokjaer and





delayed, evidence of sustained peptide release from the microparticles. Hence, peptide
loading into PSi microparticles was successful with high loading degrees (12–20% w/w)
ultimatelywithallthreeexaminedpeptides(Mw930–4050g/mol),asalsoPYY336couldbe
loaded into PSi microparticles after their suitability for peptide delivery was first
demonstrated.Whenthepeptidesizeincreasesitcanbeexpectedtooccupymorespaceon
thePSisurface(Jarvisetal.2010).Thehighestloadingdegree,20%(w/w),wasobtainedfor
the smallest peptide GhA (Mw 930 g/mol) in the most hydrophobic and stable THCPSi
microparticles (38–53 m) and the lowest 12.2% (w/w) for PYY336 (Mw 4050 g/mol) in
THCPSi microparticles (38–53 m) (Table 9.1). To summarize, the bioactivity of the
investigatedpeptideswasconfirmedinseveralparameters,invivobymeasuringfoodintake,
water consumption, blood pressure and heart rate. Furthermore, PYY336 was measured
usinganELISA,whichdetectsbioactivemolecules.Therefore, thestudyconfirmedthatPSi





and elevated PYY336 concentrations were detected in plasma after administration in PSi
micro(s.c.)andnanoparticles(s.c.andiv.).
 The acute effects of single administration of hydrophobic THCPSi micro and
nanoparticles on cytokine release were evaluated after s.c. and i.v. injections in mice,
respectively.Ingeneral,injectabledrugdeliverysystemshavebeenclaimedtoinduceforeign
body reaction,which is featured by acute and chronic inflammation, cytokine activity and
fibrous capsule formation (Anderson et al. 2008; Rodriguez et al. 2009). The results of the
present studydidnot revealanyPSi inducedpresenceof cytokines inplasma, similarly to
previous studies where hydrophilic PSi types have been evaluated (Tanaka et al. 2010a).
Despite the promising results obtained from various PSi investigations, detailed toxicity
screenings are needed for the each distinct surface type, including chronic administration.
However, according to the present knowledge, PSi basedmaterials appear to be generally
welltoleratedandsafe,henceencouragingcontinuationoffurtherdevelopment(Jaganathan
andGodin,2012).
 In thecomparisonofPSinanoandmicroparticles fors.c.peptideadministration, itwas
found thatboth formscouldactas sustained release systems. Inaddition,PSinanocarriers
appeared to be superior over microparticles for s.c. PYY336 delivery. Interestingly, the
surfacechemistryofPSimicroparticlesaffectedsignificantlythes.c.peptidedelivery,asonly
TOPSi showed complete PYY336 release (Fabs ca 100%) and increased the relative
bioavailability2.5fold(256±41%),comparedwiththes.c.solution(Table9.1).Asdiscussed
earlier, the effect of the surface chemistry may be attributed to the differences in the
hydrophilicity and rates of dissolution of different PSi types. In addition, the peptide
adsorptiononPSisurfacetakesplaceviahydrophobicandelectrostaticinteractionsandthe
strengthofinteractionsisdependentonthepropertiesofpeptideandPSisurfacetype.PYY3
36 loadings were performed in aqueous solutions, in which pH may affect the existing
electrostatic interactions. The pH values of the PYY336 loading solutions were
approximately 7or slightlyunder that, creatingpositive andnegative charges forPYY336
andPSi surfaces, respectively,whichshould facilitate theadsorption (Table9.1).FTIRdata
indicated that the weakest interactions were between TOPSi microparticles and PYY336,
whichwas reflected in the highest released fraction in vivo (Fabs ca 100%), comparedwith










Peptide YY3-36  
(PYY3-36) 
TOPSi UnTHCPSi THCPSi 
Molecular 
Weight (g/mol) 
930  1024 4050 - - - 
Isoelectric 
Pointa 
10.1 8.3 7.6 2.6 3.8 4.6 
Charge at 
physiological pH 




 Peptide release from PSi is controlled by several factors, which are not yet fully
understood. In general, the peptide release from PSi takes place by diffusion through the
solutefilledpores.Inordertobereleased,thepeptideneedstobecomedissolved,whichis
affected by the PSiwetting, hence thewettability of the PSi surface is an important factor







100%after s.c.deliveryand thismarkedly increased their relativebioavailabilities (>2fold)
(Table 9.2). The reason for the improvedpeptide release profilemight be attributed to the
relatively faster dissolution of PSi nanocarriers than microparticles, which improves PSi
dissolution controlled peptide release andmay counteract the effect of PSi surface, in this
case.Inaddition,onefacilitatingfactormightbethethousandfoldshorterdiffusionlengthof
the pores in nanoparticles (ca <170 nm), compared with the microparticles (ca <53 m).
Furthermore,sufficientabsorptionofhighPYY336dosesfromthes.c.spacemayrequirea
controlledreleasesystem,aspoorbioavailabilityofs.c.PYY336solutionwasobservedalso
in rats, but it was significantly improved by integration into the PEAH polymer, which
allowedcontrolleddeliveryofPYY336for9days(Mönkäreetal.2012).

Table 9.2. Comparison of PSi micro- and nanoparticles for s.c. PYY3-36 (20 μg) delivery in mice. 
 Microparticles Nanoparticles 
 TOPSi UnTHCPSi THCPSi TOPSi UnTHPCSi THCPSi 
Particle size 38–53 μm 38–53 μm 38–53 μm 163 nm 180 nm 157 nm 
Pore Volume 
(cm3/g) 
0.76 0.94 0.76 0.59 0.71 0.60 
Surface Area 
(m2/g) 
222  231 273 163 230 202 
Pore diameter 10.3 10.4 11.2 15.3 12.3 11.8 
Loading 
(%w/w) 
14.8 16.0 12.2 nd nd nd 
F%(abs) 98±16 9±1 13±2 81±15 103±25 84±12 
F% (rel) 256±41 25±2 34±3 211±38 270±64 219±30 
Cmax(ng/ml) 103±8 13±2 22±6 15±6 12±3 11±2 
tmax (h) 51±9 19±8 11±2 5±3 35±15 23±9 
t1/2(h) 7±1 21±2 20±1 21±1 28±4 21±2 
F%(abs): absolute bioavailability;F%(rel): relative bioavailability comparedwith s.c. delivery;Cmax: themaximumplasma concentration;
tmax:timetoachievetheCmax;t1/2:eliminationhalflife;nd:notdetermined
 Finally,whencomparings.c.and i.v.administrationroutes forpeptidedeliveryutilizing
PSi nanocarriers, nanocarriers were shown to be suitable for i.v. and s.c. administration
PYY336reflectingtheirversatileuse inpeptidedelivery.Asdescribedearlier, thedifferent
surface chemistries of PSi did not have any major effects on s.c. PYY336 delivery when
applying nanocarriers. In contrast, after i.v. administration, the surface chemistry of PSi
nanocarriers affected markedly PYY336 delivery. TOPSi and UnTHCPSi demonstrated
complete PYY336 release (Fabs ca 100%),whereas themore hydrophobic THCPSi achieved
only approximately 50% PYY336 absolute bioavailability after i.v. administration.
Unfortunately, sustained peptide release could not be achieved after i.v. delivery as the
peptideeliminationwascomparable to thatencounteredwith theplain solution.Thereare
several factors, such as hydrophilicity, shape, opsonization properties and size of
nanoparticles, which affect their circulation time (Alexis et al. 2008). PYY336 would be
expectedtobereleasedfastestfromtheparticlesurface,whichexposesthespecificproperties
oftheusedPSitype.ThemajordifferencebetweentheinvestigatedPSinanoparticletypesis
their hydrophilicity and it could be speculated that perhaps the rapid elimination of




partially responsible for the poor bioavailability of PYY336 after i.v. administration
compared with other PSi particle types. In addition, possible in vivo aggregation of the
nanoparticlesisnotknown.Drugfree,hydrophobicTHCPSinanoparticleshavebeenshown
to accumulate rapidly in liver and spleen, but the shape of the particles and surface
properties can also affect their biodistribution, for example by affecting the vascular
adhesion,organaccumulationandcellinternalization(Bimboetal.2010;Decuzzietal.2010;
Godin et al. 2010). Interestingly, a 3week sustained effect after single i.v. delivery of
multistage PSi delivery system has been reported and the authors claimed that therewas
sustainedreleasefromtheparticleswhichhadbeenretainedintheliver(Tanakaetal.2010b).
Inaddition,oxidizedPSinanoparticleshavebeenreportedtodegraderapidly,withinhours







such as PSi, is that it should be biodegradable. Hence the loaded drug can be released




complete release. In addition, in vitro release of PYY336 was poorer compared to in vivo
release from PSi microparticles. This difference might partially arise from accelerated PSi
degradation in vivo, compared with in vitro results, as described previously. This can be
affected by the porosity and surface chemistry of PSi but also by the release medium;
degradationbeingfasterinserumcomparedwithPBSmayalsobeindicativeofimprovedin
vivo dissolution (Park et al. 2009;Godin et al. 2010).TOPSi,having the fastestdegradation
rate, was the only PSi microparticle type achieving complete PYY336 release in vivo. In
addition to diffusion and PSi dissolution, also competitive adsorptionmay have a role in
controllingpeptidereleaseandthiscouldpartiallyexplaintheobserveddifferencesbetween




 In conclusion, the present study demonstrated that PSi is a novel and versatile tool for
peptide delivery. PSi prolongs the effects and improves significantly the pharmacokinetic
properties of the investigated appetite regulatingpeptides after s.c. delivery. PSi is able to
sustain the peptide release over several days after s.c. administration and that can be
controlled by modifying the PSi surface chemistry and particle size. In addition, PSi
nanocarriers can be utilized for i.v. peptide delivery. Importantly, the experiments
investigatingthebiocompatibilityandsafetypropertiesofPSiwerepromising.Thepresent
study indicates that there are good reasons to continue this line or researchwith the goal









Important pros of PSi are its ability to carry sufficient peptide payloads and capability to
maintain the biological activity of peptides. Moreover, the surface functionalization and
tuneable porousproperties can be used to finetune peptide loading and release behavior.
However, the factors affecting successful peptide delivery using PSi (i.e. porosity, surface
chemistry, particle size, release medium, administration route and properties of the used
peptide) are not yet completely understood. Therefore, amoredetailed characterization of
factors controlling peptide adsorption and release and improved prediction of the in vivo
release profile with the help of in silico modeling is needed. It must be noted that the
peptides, which were used in this study served as model compounds. All the needed
characterization,includingdetailedevaluationofparticleproperties(e.g.pores,surface,size
and shape), peptide loading and release in rational pH range, biodistribution,
biodegradation,therapeuticalefficacy,toxicity,stabilityetc.shouldbefinallycarriedoutwith
aclinicallyrelevantpeptidecombinedwithaPSitypehavingtheoptimalpropertiesforthe
specific peptide. In addition, the production of the formulation should be optimized and
scaledup,whenfinalizingaproductforclinicaluse.
 Thisstudydemonstratedsustainedpeptidereleaseover4days,whichmaybeconsidered





structure and thework isplanned toperform in the future. It is engouraging thatpeptide
deliveryviaPSinanocarriersalreadyimprovedplasmaconcentrationprofilecomparedwith
microparticlesinthepresentstudy.Inaddition,PSiformulationswouldbeeventuallyused




route and they can be formulated also as tablets,whereas the size of the investigated PSi
microparticlesmeans that they are restricted generally to s.c. and p.o. routes (Wang et al.
2010;Tahvanainenetal.2012).PSiissuitablealsoforperoraladministrationandithasbeen
demonstratedtoimprovethepermeabilityof insulinacrossCaco2cellsandhence,PSimay
have potential for oral peptide delivery (Foraker et al. 2003). Therefore, it would be
interestingtoevaluatethepossibilityofutilizingPSiinaperoralpeptidedeliverysystem.
 To summarize, this work demonstrated for the first time the suitability of PSi for
controlled peptide delivery after s.c administration and created the basis for this line of








suchas rapid invivodegradation,hamper their exploitationaspharmaceutical compounds
andthusimprovedpeptidedeliverysystemsareneeded.Therefore,thesuitabilityofanovel
material, PSi, as away of achieving improvedpeptide deliverywas investigated by using




peptidesghrelin antagonist andmelanotan II, it is concluded thatPSi is suitable for
controlled s.c. peptide delivery. THCPSi microparticles maintained the peptides’
biological activities and sustained their release, as their pharmacologic effects were
prolongedinmiceandrats.

2. No changes in plasma cytokine levels were detected after single s.c. or i.v.




3. The surface chemistry of PSimicroparticles affected the s.c. peptidedelivery, as the
releasedPYY336fractiondecreasedwiththehydrophobicityofthePSisurface.PYY3
36 release was complete only from TOPSi microparticles. In contrast, the surface
chemistry of s.c. nanocarriers did not significantly affect PYY336 release, since the
releasewascomplete fromall thePSi formulations.One favourableobservationwas
thatall thestudiedPSi formulations (TOPSi,UnTHCPSiandTHCPSi)enabled long
terms.c.deliveryofpeptideYY336, i.e. they sustainedpeptide releaseover 4days.
However, the PSi nanocarriers further enhanced s.c. PYY336 delivery due to
improved release and a more stable plasma concentration profile, when compared
withmicroparticles.

4. Both, s.c. and i.v. delivered PSi nanocarrierswere shown to be suitable for peptide







material for fragile peptidemolecules, preserving the activity and achieving sustained s.c.
releaseofpeptidesandevokingnoinflammatorysignsafteradministration.Furthermore,the
peptidereleasecanbealteredbychanging thePSisurfacechemistry.WhencomparingPSi
micro and nanoparticles for s.c. peptide delivery, the latter seemed to provide a more
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Mesoporous Silicon Micro- and 
Nanoparticles – A Versatile Tool for 
Peptide Delivery
It is likely that peptides will increase 
their share of pharmaceuticals 
replacing the traditional drug 
compounds, but their successful 
delivery is challenged by 
their physicochemical and 
pharmacokinetic properties. 
Therefore, improved delivery 
systems are needed to facilitate the 
clinical use of peptides. In this thesis, 
mesoporous silicon was demonstrated 
to be suitable and tuneable material 
for controlled peptide delivery in 
vivo.
